[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8109
1. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


2. Strasser AA, Cappella JN, Jepson C, Fishbein M, Tang KZ, Han E, Lerman C: Experimental evaluation of antitobacco PSAs: effects of message content and format on physiological and behavioral outcomes. Nicotine Tob Res; 2009 Mar;11(3):293-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental evaluation of antitobacco PSAs: effects of message content and format on physiological and behavioral outcomes.
  • INTRODUCTION: Antitobacco media campaigns using public service announcements (PSAs) have shown promise in reducing smoking initiation and increasing intentions to quit.
  • Research on what makes an effective PSA has had mixed outcomes.
  • The present study tested the effects of specific message features in antitobacco PSAs, using theory-based physiological and self-report outcomes.
  • METHODS: PSAs were categorized as high or low in message sensation value (MSV) and strength of argument and presented to 200 current smokers in a 2 x 2 factorial design.
  • Physiological responses-specifically, heart rate, skin conductance, zygomaticus major, and corrugator supercilii-were assessed while participants viewed the PSAs.
  • Among those low in sensation seeking, low MSV PSAs elicited higher self-efficacy, whereas the reverse was true for high sensation seekers.
  • High MSV PSAs elicited higher negative beliefs in low sensation seekers.
  • DISCUSSION: The present study represents the first comprehensive theory-based experimental investigation of the effects of different features of antitobacco PSAs and provides a framework for future research in identifying effective features of such PSAs.
  • Results illustrate the importance of considering individual differences, characterizing both PSA content and format, and outcome and response measures when evaluating antitobacco PSAs.

  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Clin Psychopharmacol. 1999 Nov;7(4):493-501 [10609984.001]
  • [Cites] Psychophysiology. 1993 May;30(3):261-73 [8497555.001]
  • [Cites] AIDS Care. 2000 Jun;12(3):273-8 [10928203.001]
  • [Cites] BMJ. 2000 Aug 5;321(7257):351-4 [10926595.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1772-7 [11114317.001]
  • [Cites] Am J Public Health. 2001 Feb;91(2):233-8 [11211631.001]
  • [Cites] Am J Public Health. 2001 Feb;91(2):292-6 [11211642.001]
  • [Cites] Am J Health Behav. 2001 Mar-Apr;25(2):147-56 [11297044.001]
  • [Cites] Drug Alcohol Depend. 2001 May 1;62(3):195-203 [11295324.001]
  • [Cites] Am J Public Health. 2002 Jun;92(6):908-16 [12036776.001]
  • [Cites] JAMA. 2002 Jun 12;287(22):2983-9 [12052128.001]
  • [Cites] Health Commun. 2002;14(4):403-28 [12375769.001]
  • [Cites] Health Psychol. 1997 Jan;16(1):87-99 [9028818.001]
  • [Cites] JAMA. 1998 Jul 22-29;280(4):323; author reply 324 [9686542.001]
  • [Cites] Health Psychol. 1999 Jan;18(1):89-94 [9925050.001]
  • [Cites] Subst Use Misuse. 1999 Feb;34(3):455-68 [10082067.001]
  • [Cites] Am J Public Health. 2005 Mar;95(3):425-31 [15727971.001]
  • [Cites] Health Commun. 2005;17(3):283-300 [15855074.001]
  • [Cites] Arch Pediatr Adolesc Med. 2005 Jul;159(7):639-45 [15996997.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Oct 28;54(42):1077-80 [16251864.001]
  • [Cites] J Epidemiol Community Health. 2007 Apr;61(4):298-301 [17372288.001]
  • [Cites] Ethn Health. 2007 Sep;12(4):339-62 [17701761.001]
  • [Cites] Am J Public Health. 2007 Sep;97(9):1644-9 [17395843.001]
  • [Cites] Exp Clin Psychopharmacol. 2001 May;9(2):183-90 [11518094.001]
  • [Cites] Am J Public Health. 2002 Feb;92(2):238-45 [11818299.001]
  • [Cites] Hum Commun Res. 1998 Mar;24(3):454-68 [12293438.001]
  • [Cites] Annu Rev Public Health. 2002;23:45-71 [11910054.001]
  • [Cites] Tob Control. 2002 Jun;11 Suppl 2:ii43-6 [12034981.001]
  • [Cites] Am J Public Health. 2002 Jun;92(6):901-7 [12036775.001]
  • [Cites] J Health Commun. 2003 Mar-Apr;8(2):129-43 [12746037.001]
  • [Cites] J Health Commun. 2003 May-Jun;8(3):229-47 [12857653.001]
  • [Cites] Psychophysiology. 2003 Sep;40(5):776-85 [14696731.001]
  • [Cites] Prev Med. 2004 Oct;39(4):695-703 [15351535.001]
  • [Cites] J Health Commun. 2004 May-Jun;9(3):259-74 [15360037.001]
  • [Cites] NIDA Res Monogr. 1983;47:5-35 [6419119.001]
  • [Cites] J Pers. 1990 Mar;58(1):313-45 [2198341.001]
  • [Cites] Br J Addict. 1991 Sep;86(9):1119-27 [1932883.001]
  • [Cites] Am J Public Health. 2000 Mar;90(3):380-6 [10705855.001]
  • (PMID = 19246628.001).
  • [ISSN] 1469-994X
  • [Journal-full-title] Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • [ISO-abbreviation] Nicotine Tob. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095856; None / None / / P50 CA095856-05; United States / NCI NIH HHS / CA / CA101404; United States / NCI NIH HHS / CA / P50 CA095856-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2666374
  •  go-up   go-down


3. Riedinger JM, Eche N, Fulla Y, Thuillier F: [PSA kinetics after total prostatectomy]. Ann Biol Clin (Paris); 2009 Jan-Feb;67(1):39-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PSA kinetics after total prostatectomy].
  • [Transliterated title] Cinétique du PSA après prostatectomie totale.
  • The prostate specific antigen (PSA) is the best marker of the prostate cancer today although not very specific of this pathology.
  • With the lack of residual cancer, PSA becomes undetectable by the first month after total prostatectomy: less than 0.1 microg/L.
  • Faced with residual cancer, PSA either does not become undetectable or increases after an initial undetectable period.
  • A recurrence is defined by a value of PSA higher than 0.2 microg/L and confirmed on two successive assays.
  • The time of appearance of the recurrence and the PSA doubling time after total prostatectomy have, with the initial clinical stage and the Gleason score, a diagnostic value on the nature of the site of recurrence, local or metastatic.
  • [MeSH-minor] Biomarkers, Tumor / blood. Follow-Up Studies. Humans. Male. Neoplasm Staging. Time Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189884.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 67
  •  go-up   go-down


Advertisement
4. Riedinger JM, Eche N, Bachaud JM, Crehange G, Fulla Y, Thuillier F: [PSA kinetics after radiotherapy]. Ann Biol Clin (Paris); 2009 Jul-Aug;67(4):395-404
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PSA kinetics after radiotherapy].
  • [Transliterated title] Cinétique de PSA après radiothérapie.
  • The prostate specific antigen (PSA) is the best marker of the prostate cancer today although not very specific of this pathology.
  • After radiotherapy, PSA can decrease after a mean interval of one to two years to a value less than 1 microg/L (predictive of recurrence-free survival).
  • Biochemical recurrence after radiotherapy is defined by an increase of PSA by 2 microg/L or more above the PSA nadir, whether or not it is associated with endocrine therapy.
  • The time of appearance of the recurrence and the PSA doubling time after total radiotherapy have a diagnostic value on the nature of the site of recurrence, local or metastatic.
  • [MeSH-minor] Aged. Follow-Up Studies. Half-Life. Humans. Kinetics. Male. Middle Aged. Neoplasm Metastasis. Time Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656762.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 77
  •  go-up   go-down


5. van Hooft IM, Zeebregts CJ, van Sterkenburg SM, de Vries WR, Reijnen MM: The persistent sciatic artery. Eur J Vasc Endovasc Surg; 2009 May;37(5):585-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The persistent sciatic artery.
  • BACKGROUND: A persistent sciatic artery (PSA) is a rare vascular anomaly with an estimated incidence of 0.03-0.06%.
  • During early embryonic development, the sciatic artery usually disappears when the superficial femoral artery has developed properly.
  • This study aimed to assess the clinical presentation and outcome of a PSA.
  • METHOD: A systematic review of all cases of PSA published between 1964 and 2007 was performed.
  • RESULTS: In this review, 159 PSAs were described in 122 patients.
  • The mean age at which the PSA was discovered was 57 years, and the incidence was equally distributed with regards to gender.
  • The majority of PSAs was unilateral (70%) and of the complete type (79%).
  • An aneurysm was found in 48%, a stenosis in 7%, an occlusion of the PSA in 9% and an occlusion of an artery distal to the PSA in 6% of the subjects.
  • The treatment depended on the symptoms and classification of the PSA.
  • CONCLUSION: The PSA is a rare anomaly with a high incidence of complications including aneurysm formation and ischaemia that may lead to amputation.
  • [MeSH-minor] Angiography. Diagnosis, Differential. Global Health. Humans. Incidence. Prognosis. Stents. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231248.001).
  • [ISSN] 1532-2165
  • [Journal-full-title] European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
  • [ISO-abbreviation] Eur J Vasc Endovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


6. Deslauriers V, Rouleau DM, Alami G, MacDermid JC: Translation of the Patient Scar Assessment Scale (PSAS) to French with cross-cultural adaptation, reliability evaluation and validation. Can J Surg; 2009 Dec;52(6):E259-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translation of the Patient Scar Assessment Scale (PSAS) to French with cross-cultural adaptation, reliability evaluation and validation.
  • BACKGROUND: Patient esthetic satisfaction related to scarring after orthopedic surgery was rarely assessed before the development of the Patient Scar Assessment Scale (PSAS).
  • The purpose of our study was to translate and validate the PSAS and assess the psychometric properties of the French version.
  • First, 2 independent translators completed the forward translation of the PSAS and then met to achieve a consensus version.
  • We assessed the test-retest reliability of the new French scale, which was filled out twice by a cohort of 53 patients, using scale distribution analysis, internal consistency (Chronbach alpha) and absolute agreement (intraclass correlation coefficients [ICC (2,1)]).
  • The reliability of the translated version (PSAS-Fr) and its internal consistency was high (Chronback alpha 0.87-0.98 for each of the 6 questions), and the test-retest reliability was excellent (ICC 0.96).
  • CONCLUSION: The PSAS-Fr was successfully translated from the original English version and demonstrated strong cross-sectional psychometric properties.

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Scars.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Psychiatry. 2005 Jan;50(1):67-71 [15754668.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):953-9 [9817112.001]
  • [Cites] J Hand Surg Am. 2005 May;30(3):493-9 [15925158.001]
  • [Cites] Plast Reconstr Surg. 2005 Oct;116(5):1291-9 [16217470.001]
  • [Cites] Clin Orthop Relat Res. 2005 Dec;441:80-5 [16330988.001]
  • [Cites] J Hand Surg Am. 2006 Feb;31(2):289-94 [16473693.001]
  • [Cites] BMC Musculoskelet Disord. 2006;7:13 [16478541.001]
  • [Cites] Plast Reconstr Surg. 2006 Mar;117(3):1036-7 [16525305.001]
  • [Cites] BMC Musculoskelet Disord. 2006;7:25 [16529658.001]
  • [Cites] J Occup Rehabil. 2007 Dec;17(4):701-11 [17909949.001]
  • [Cites] World J Surg. 2008 Jan;32(1):45-50 [17990025.001]
  • [Cites] J Bone Joint Surg Am. 2008 Jan;90(1):2-9 [18171951.001]
  • [Cites] World J Surg. 2008 Jul;32(7):1341-8 [18373119.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91 [11124735.001]
  • [Cites] Arch Phys Med Rehabil. 2002 Mar;83(3):376-82 [11887120.001]
  • [Cites] Arch Surg. 2002 Mar;137(3):301-4; discussion 305 [11888453.001]
  • [Cites] Occup Ther Int. 2002;9(1):76-89 [12375009.001]
  • [Cites] J Burn Care Rehabil. 2003 Jul-Aug;24(4):239-44; discussion 238 [14501421.001]
  • [Cites] Plast Reconstr Surg. 2004 Jun;113(7):1960-5; discussion 1966-7 [15253184.001]
  • [Cites] Stat Med. 1987 Jun;6(4):441-8 [3629046.001]
  • [Cites] Dermatol Clin. 1993 Oct;11(4):697-708 [8222353.001]
  • [Cites] J Bone Joint Surg Am. 2005 Apr;87(4):701-10 [15805196.001]
  • (PMID = 20011161.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2792396
  •  go-up   go-down


7. Treatment for hair loss affects prostate specific antigen. Nurs Stand; 2007 Mar 07;21(26):17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : The recommendation for the adjustment of serum prostate-specific antigen (PSA) concentration for screening in men taking 5mg/day finasteride for benign prostatic hyperplasia should also apply to men taking 1mg/day for male pattern hair loss.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967427.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Kandasamy J, Smith A, Diaz S, Rose B, O'Brien C: Heterogeneity of PLAG1 gene rearrangements in pleomorphic adenoma. Cancer Genet Cytogenet; 2007 Aug;177(1):1-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of PLAG1 gene rearrangements in pleomorphic adenoma.
  • Pleomorphic adenoma (PA), a benign mixed salivary gland tumor, has been associated with abnormal karyotypes in up to 70% of cases, with nonrandom involvement of 8q12, the locus of the pleomorphic adenoma (PLAG1) gene.
  • Samples of parotid gland tissue from the tumor sites, set up as solid tumor cultures, showed a normal karyotype in two cases [46,XY;46,XX] and cytogenetic abnormalities in five cases (71%).
  • FISH was performed in all cases by using two probes from the RP11 library, flanking PLAG1; a sequence 1.48 megabases (Mb) upstream and another 2.27 Mb downstream, covering a total area of 3.8 Mb.
  • [MeSH-major] Adenoma, Pleomorphic / genetics. DNA-Binding Proteins / genetics. Gene Rearrangement. Genetic Variation. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693184.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / PLAG1 protein, human
  •  go-up   go-down


9. Linebarger DL, Piotrowski JT: Evaluating the educational potential of health PSAs with preschoolers. Health Commun; 2008 Nov;23(6):516-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating the educational potential of health PSAs with preschoolers.
  • Children learn from a variety of televised programs, including the short public service announcements (PSAs) that air between children's programs.
  • PSAs are designed to repetitively expose children to important content ranging from the benefits of reading to health-related messages.
  • The purpose of this study was to evaluate 5 PSAs containing health messages for preschoolers (i.e., nutrition, physical activity, and hand washing).
  • Child PSA viewers were able to recall more of the educational content, apply this knowledge to specific choices contained in each message, and transfer this knowledge to novel situations compared with their nonviewing counterparts.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19089699.001).
  • [ISSN] 1532-7027
  • [Journal-full-title] Health communication
  • [ISO-abbreviation] Health Commun
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Nan X, Zhao X: The influence of liking for antismoking PSAs on adolescents' smoking-related behavioral intentions. Health Commun; 2010 Jul;25(5):459-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of liking for antismoking PSAs on adolescents' smoking-related behavioral intentions.
  • In this research, we examine the influence of liking for antismoking public service announcements (PSAs), relative to that of PSAs' perceived argument strength, on adolescents' smoking-related behavioral intentions.
  • Data from the first Legacy Media Tracking Survey (LMTS-I) suggest that the relative persuasive impact of PSA liking and perceived argument strength varies as a function of message recipients' smoking status.
  • PSA liking appears to be an important predictor of smoking intentions for never smokers, whereas perceived argument strength strongly predicts quitting intentions for current smokers.
  • For former smokers, both perceived argument strength and PSA liking have significant effects on smoking intentions, with perceived argument strength exerting a stronger impact.


11. Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E: [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)]. Arch Esp Urol; 2005 Jun;58(5):403-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
  • [Transliterated title] Ventajas y riesgos de la utilización del antígeno prostático específico (PSA) en el area sanitaria v de Gijón (Asturias).
  • OBJECTIVES: The diagnosis of prostate cancer has changed significantly with the introduction of PSA in the clinical practice.
  • Despite screening is under controversy the use of PSA has become widespread.
  • The objective of this paper is to know the use of PSA in our health-care area and to analyze perceived risks and benefits.
  • METHODS: From the informatic archives we analyze PSA determinations performed in our health-care area (290.956 citizens) over 2000 and 2001.
  • RESULTS: 25.519 PSA determinations were performed.
  • PSA was normal in 78.7% of the patients and higher than 4 ng/ml in 21.2%.
  • Depending on the first PSA, diagnosis was started by a GP in 44% of the cases, a urologist in 46%, and the remaining 10% by other specialists.
  • Mean time from first PSA to diagnosis was 5 months, without significant differences between GPs and specialities .
  • The use of PSA by GPs is variable (between 8.1 and 45.8 determinations per 100 men over 50 years), without significant differences in prostate cancer detection by number of PSAs or differences in age.
  • There is a greater incidence and increase of cancer in the rural area (from 33.52 to 221.1 new cases/ 100.000 inhabitants/year).
  • CONCLUSIONS: We confirm the general use of this test and the trend to screening in the primary health-care level, which participates in an important manner in the diagnosis.
  • PSA brings forward the diagnosis of prostate cancer 5 years in our area, and shoots its incidence rates.
  • The high use of such marker in our population of advanced age may be considered inadequate.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Mass Screening / statistics & numerical data. Neoplasm Proteins / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Early Diagnosis. Humans. Incidence. Male. Middle Aged. Predictive Value of Tests. Primary Health Care / statistics & numerical data. Prostate / pathology. Referral and Consultation / statistics & numerical data. Retrospective Studies. Risk. Sensitivity and Specificity. Spain / epidemiology. Urology / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078781.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


12. Börgermann C, Loertzer H, Luboldt HJ, Hammerer P, Fornara P, Graefen M, Rübben H: [PSA--Quo vadis?]. Urologe A; 2009 Sep;48(9):1008, 1010, 1012-4, passim
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PSA--Quo vadis?].
  • [Transliterated title] PSA--Quo vadis?
  • Digital rectal examination is supplemented by determination of prostate-specific antigen (PSA).
  • Before the first PSA test, the patient must be informed of possible consequences such as biopsy recommendation and treatment options.
  • [MeSH-major] Ambulatory Care / methods. Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54 [18695132.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2713-9 [15187052.001]
  • [Cites] J Urol. 2000 Dec;164(6):1964-7 [11061892.001]
  • [Cites] BJU Int. 2000 Jun;85(9):1063-6 [10848695.001]
  • [Cites] Urology. 1999 Jan;53(1):126-30 [9886601.001]
  • [Cites] J Urol. 1994 May;151(5):1283-90 [7512659.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):281-6 [12124827.001]
  • [Cites] J Urol. 1995 Aug;154(2 Pt 1):460-5 [7541864.001]
  • [Cites] World J Urol. 2007 Mar;25(1):3-9 [17364211.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):823-4 [18281649.001]
  • [Cites] Eur Urol. 2003 May;43(5):478-84 [12705990.001]
  • [Cites] JAMA. 1995 Jan 25;273(4):289-94 [7529341.001]
  • [Cites] Urology. 2004 Feb;63(2):316-20 [14972481.001]
  • [Cites] Urology. 2006 Feb;67(2):316-20 [16442597.001]
  • [Cites] JAMA. 2000 Sep 20;284(11):1399-405 [10989402.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1297-301 [15371827.001]
  • [Cites] N Engl J Med. 1996 Aug 1;335(5):304-10 [8663870.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1310-9 [19297565.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Apr;50(1):71-8 [15094160.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):646-54 [16021571.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1521-7 [17077354.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Lancet. 1994 Dec 10;344(8937):1594-8 [7527116.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):835-41 [18281654.001]
  • [Cites] Urologe A. 1999 Mar;38(2):114-23 [10231930.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1510-5 [17925534.001]
  • [Cites] JAMA. 1997 May 14;277(18):1456-60 [9145718.001]
  • [Cites] Urology. 2007 Jan;69(1):134-8 [17270635.001]
  • [Cites] J Urol. 2006 Sep;176(3):979-84; discussion 984 [16890675.001]
  • [Cites] Invest Urol. 1979 Sep;17(2):159-63 [89106.001]
  • [Cites] J Urol. 1996 Jul;156(1):127-32 [8648773.001]
  • [Cites] Eur Urol. 2007 Feb;51(2):366-74; discussion 374 [16930812.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1831-6 [7523730.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):37-44 [17826892.001]
  • [Cites] BJU Int. 2005 Feb;95(2):231-7 [15667646.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):215-24 [12824459.001]
  • [Cites] Ann Clin Biochem. 2001 May;38(Pt 3):188-216 [11392495.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1973-8 [17886252.001]
  • [Cites] J Urol. 2005 Aug;174(2):489-94; discussion 493-4 [16006878.001]
  • [Cites] JAMA. 1992 Apr 22-29;267(16):2215-20 [1372942.001]
  • [Cites] Urology. 2005 Feb;65(2):343-6 [15708050.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):398-403 [19064972.001]
  • [Cites] Eur Urol. 1998;33(3):261-70 [9555550.001]
  • [Cites] Clin Chem. 2006 Jan;52(1):59-64 [16391327.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):292-306 [14976540.001]
  • [Cites] J Urol. 2007 Mar;177(3):899-902 [17296371.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1320-8 [19297566.001]
  • [Cites] Urology. 2001 Sep;58(3):411-6 [11549490.001]
  • [Cites] Eur Urol. 2005 Oct;48(4):541-5 [16139417.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1462-6 [14519752.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 2):S48-50; discussion S50-1 [15535443.001]
  • [Cites] Eur Urol. 2000 Jun;37(6):670-4 [10828666.001]
  • [Cites] Clin Chem. 2005 Aug;51(8):1342-51 [15961552.001]
  • [Cites] J Urol. 2000 Aug;164(2):411-5 [10893598.001]
  • (PMID = 19680620.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 61
  •  go-up   go-down


13. Ponholzer A, Stoiber F, Loidl W, Rauchenwald M, Schramek P, Madersbacher S: [How to use PSA in 2009]. Wien Med Wochenschr; 2009;159(21-22):515-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How to use PSA in 2009].
  • [Transliterated title] Aktueller Einsatz von PSA.
  • PSA is without any doubt the most frequently used marker in urology due to its helpful information regarding various aspects of diagnosis, therapy and prognosis in men with prostate cancer.
  • On the other hand, many controversies still exist about the various indications for PSA-determination.
  • The following overview is aimed to analyse the current status of PSA in the management of men undergoing screening, therapy or follow-up of prostate cancer.
  • Anyhow, a detailed knowledge of how to use and interpret PSA and PSA-kinetics is considered to play a crucial role in prostate cancer patients.
  • Current strategies are aimed to start and stop PSA-use earlier.
  • [MeSH-major] Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Algorithms. Biopsy. Early Diagnosis. Humans. Male. Mass Screening. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Prostate / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997836.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 25
  •  go-up   go-down


14. Rybikowski S, Maurin C, Deturmeny J, Delaporte V, Lechevallier E, Coulange C: [PSA and spironolactone]. Prog Urol; 2010 Feb;20(2):154-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PSA and spironolactone].
  • [Transliterated title] PSA et spironolactone.
  • We report the case of a 72-year-old man having a cancer of prostate which normalized its PSA after institution of a treatment by spironolactone for ascites.
  • [MeSH-minor] Aged. Androgen Antagonists / therapeutic use. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier Masson SAS.
  • (PMID = 20142058.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 27O7W4T232 / Spironolactone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


15. Feyerabend S, Stefanovic S, Gouttefangeas C, Widenmeyer M, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Rammensee H, Stenzl A: HLA-associated multipeptide vaccination in biochemically relapsed prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Study endpoints are side effects as well as PSA- and T-cell response.
  • METHODS: Patients (pts) with rising PSA after primary curative surgical treatment without metastatic imageable lesions receive 14 peptides emulsified in Montanide ISA51 subcutaneously, combined with one of four T-cell stimulatory adjuvants versus no adjuvant for 18 months (mo) or until progression.
  • PSA doubling time (DT) and clinical performance are monitored.
  • During the vaccination period, geometric mean PSA DT increased from 7.8 mo (range 1.5 - 44.8 mo, 25 pts) to 11.8 months (range 2.2 - 571.3 mo, 24pts) whereas 1 pt showed a decreasing PSA value.
  • Overall 8/25 pts (32%) had a mean rise of PSA DT of 81.6 mo and four of them did not receive any further treatment and were evaluable for follow-up (FU) after peptide vaccination (FU median 16 mo, range 5-33).
  • These four pts raised their mean geometric PSA DT from 8.2 mo prior study treatment to 51.9 mo at treatment end and 52.5 mo at end of FU.
  • PSA progressed unchanged in 10 patients (40%) or increased intermittently only in 4 pts.
  • Two pts had PSA decline or DT increase during FU but not during the treatment period.
  • All pts reacted to at least one of the tumor antigen-derived HLA-class I epitopes after the fourth vaccine injection and up to six peptides were recognized simultaneously by CD8+ T cells in some individuals.
  • CONCLUSIONS: Multi peptide vaccination stabilized or slowed down PSA progress in 11 of 25 cases.
  • Rise of PSA DT delaying standard treatment up to 33 mo and thus, delaying disease specific mortality is feasible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964428.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Drewnowska K, Crawford ED, Qian J, Varvel S, Wilk M, Mason L, Kaminetsky J, Huisman TK, Bilowus M, Freedman SJ, Bostwick DG: PCA3: A urine-based genetic assay for detection of prostate cancer in men with elevated PSA. J Clin Oncol; 2009 May 20;27(15_suppl):5054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCA3: A urine-based genetic assay for detection of prostate cancer in men with elevated PSA.
  • : 5054 Background: Currently, early detection of prostate cancer relies primarily on an abnormal digital rectal examination (DRE) and an elevated prostate-specific antigen (PSA) level leading to a prostate biopsy.
  • However, because of low positive predictive values, up to 75% of men with elevated PSA and/or suspicious DRE have a negative biopsy.
  • Urine samples were obtained from 974 men with elevated serum PSA (> 2.5ng/ml) and/or abnormal digital rectal examination prior to routine minimum 10-core prostate biopsy following standard study protocol in 30 medical practices.
  • PCA3 and PSA mRNA were isolated, amplified and quantified by magnetic target capture, transcription-mediated amplification, and chemiluminescent hybridization protection assay technologies.
  • The PCA3 value was determined using the ratio of PCA3 mRNA copy number to the PSA mRNA copy number multiplied by 1,000.
  • An additional 106 cases (11%) had only high-grade PIN and/or atypical small acinar proliferation suspicious for cancer (ASAP), and 488 cases (50%) were benign.
  • PCA3 had a specificity of 77% and a sensitivity of 44% for the diagnosis of prostate cancer, while the specificity and sensitivity for serum PSA were 22% and 87%, respectively.
  • CONCLUSIONS: We found that the PCA3 urine test significantly improved the specificity for the detection of prostate cancer compared to serum PSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962974.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Medioni J, Deplanque G, Maurina T, Ferrero JM, Rodier JM, Raymond E, Allyon J, Kalla S, Dufour-Lamartinie JF, Oudard S: Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):5151

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients.
  • Calcemia, creatininemia and CBC were assessed weekly; biochemistry, ECG and PSA every 3 weeks.
  • Efficacy endpoint was PSA response defined as ≥30% decline within 3 months.
  • RESULTS: Five dose levels: 40, 80, 160, 300, 600 μg have been evaluated in 34 pts; 9 pts are still being treated at 600 μg; 25 pts have completed 6 cycles (13 bone metastases; 3 extrasqueletic metastasis, 8 bone and extrasqueletic metastases; 1 PSA-only disease).
  • Median age was 72 years (range, 53-87), median Gleason score (Gs) 7 (36% Gs 10-8, 64% Gs 7-6) and median PSA 41.5 ng/mL (range, 0.9-962.4).
  • Of the 23 evaluable pts for PSA response, 20 (87%) had ≥30% PSA decline.
  • PSA responses with this combination are encouraging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E, Ko YJ, Sridhar SS, Chi KN: A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol; 2009 May 20;27(15_suppl):5139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PSA response rate (≥50% decline) was the primary endpoint (H0 = 15%, H1 = 25%, α = 0.1, β = 0.2).
  • Baseline characteristics (range): median age 67 (47-85), PSA 212 (2.6-11520), hemoglobin 118 (89-160), median time to progression after docetaxel 1.0 months (0.0-6.0), number of prior chemotherapy regimens 1:2:3+ in 45:28:10 pts, ECOG PS 0-1:2 in 73:10 pts, disease in bone/lymph nodes/viscera in 76/47/14 pts respectively.
  • In 78 pts evaluable for PSA response, PSA declines of ≥30% and ≥50% have occurred in 44/78 (56%) and 35/78 (45%) with a confirmed PSA response in 25 pts (32%).
  • Pain response (2 point decline on 6 point scale) occurred in 36 (51%) of 71 pts eligible for analysis.
  • Median PFS for PSA and non-PSA outcomes (measurable disease/symptomatic progression or death) was 7.6 months (3.7-11.5) and 5.6 months (3.9-7.3) respectively.
  • CONCLUSIONS: Patupilone 8 mg/m<sup>2</sup> every 3 weeks was well tolerated and associated with encouraging PFS, PSA and pain responses in pts with docetaxel resistant/refractory disease.
  • Further investigation of patupilone in this population is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964422.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Wang Y, Prostate Cancer Clinical Trials Consortium: Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5059 Background: Epothilones comprise a new class of microtubule stabilizing agents, and sagopilone is a novel, fully synthetic epothilone that has shown significant activity against a broad range of tumor models.
  • The primary efficacy evaluation was based on PSA decline (≥50% PSA reduction confirmed at least 28 days apart).
  • Median PSA was 107.5 (6.2-1727) ng/ml.
  • Two patients did not meet all eligibility criteria and were excluded from efficacy analyses; 3 additional patients were excluded from PSA decline and progression-free survival analyses due to missing baseline PSA assessment.
  • Twenty of 48 patients (42%; 80% CI: 32%-52%) had a confirmed PSA decline in excess of 50% and 30 (63%; 95% CI: 47%-76%) had a 30% reduction in PSA within 3 months of enrollment.
  • CONCLUSIONS: Sagopilone is active in metastatic chemotherapy-naïve CRPC patients, with probability of PSA decline, measurable disease responses, and PFS approximating the current standard of docetaxel + prednisone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962969.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nanda A, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV: Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with radiation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):9543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study cohort comprised 1,978 men of median age 71 (interquartile range [IQR], 66-75) years with intermediate-risk prostate cancer (Gleason score 7 with PSA 20 ng/mL or less and tumor category T2c or less).
  • Fine and Gray's multivariable competing risks regression was used to assess whether presence of cardiovascular disease (CVD), age, treatment, year of brachytherapy, PSA level, or tumor category were associated with the risk of PCSM.
  • The presence of CVD was significantly associated with a decreased risk of PCSM (AHR 0.20, 95% CI 0.04 - 0.99, P = 0.05), whereas an increasing PSA level was significantly associated with an increased risk of PCSM (AHR 1.14, 95% CI 1.02 - 1.27, P = 0.02).
  • In the absence of CVD, cumulative incidence estimates of PCSM were higher (P = 0.03) in men with PSA levels above as compared to the median PSA level (7.3 ng/mL) or less; however, in the setting of CVD there was no difference (P = 0.27) in these estimates stratified by the median PSA level (6.9 ng/mL).
  • CONCLUSIONS: Detection of intermediate-risk prostate cancer in elderly men without CVD at lower PSA levels is associated with a lower risk of PCSM; this risk reduction is not observed in men with known CVD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963605.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Dickstein RJ, Kreshover JE, Milose JC, Gignac GA: Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era. J Clin Oncol; 2009 May 20;27(15_suppl):e16159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era.
  • Prostate-specific antigen (PSA) screening dramatically diminished the presentation of patients (pts) with metastatic CaP from 5.6% in 1990 to 1.5% in 2003 as evidenced by the CaPSURE database.
  • Our institution has a uniquely diverse demographic and socioeconomic population and we sought to identify pts with metastatic CaP at diagnosis to evaluate contributing factors.
  • RESULTS: Sixty-one pts presented initially with metastatic CaP at a median age of 68 years old (45 -90) and a median PSA of 92 ng/mL (4.4 -3463).
  • Forty-seven pts (77%) underwent prostate biopsy of which 33 (70%) had high grade (Gleason ≥ 8) tumor.
  • CONCLUSIONS: CaP initially presenting as metastatic disease is a rare event in the post-PSA era, but may result from lacking primary health care screening, poor patient compliance, or inherent predisposing factors of tumor biology.
  • Our analysis identifies a predominantly non-Caucasian population of patients, contrasting the CaPSURE database, who are otherwise healthy.
  • We plan on performing comprehensive analyses on all patients with metastatic CaP at Boston Medical Center.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Orovan WL: Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients. J Clin Oncol; 2009 May 20;27(15_suppl):5117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were followed (median: 12; range 3-24 months) with PSA measurement every 3 months.
  • Patients who received prior radiation or hormonal therapy (n=25) and patient for whom at least 2 consecutive PSA measurements were not available (n = 32) were excluded, leaving a total of 196 patients for analysis.
  • Mean pre-treatment PSA was 6.9+3.3.
  • Biopsy Gleason scores at diagnosis (median 9 cores) were 5, 6, 3+4, 4+3 in 1, 91, 66 and 38 patients, respectively.
  • Biochemical failure (BCF) is reported using the Stephenson (PSA >0.4ng/ml and rising), Horwitz (2 consecutive increases of at least 0.5ng/ml) and Phoenix (nadir+2ng/ml) definitions.
  • RESULTS: 196 patients (age: 64+8) met the inclusion criteria for analysis.
  • Mean and median absolute PSA nadir levels were 0.28+0.53 and 0.06 ng/ml respectively.
  • Predictors of BCF were absolute nadir [HR: 3.0 (2.3-3.8)] and pre-treatment PSA [HR: 1.1 (1.0-1.2)].
  • Pre-HIFU PSA and post-HIFU PSA nadir levels are predictors for BCF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Lubaroff DM, Vaena DA, Williams RD, Joudi FN, Smith MC, Zehr PS, Eastman J, Griffith K, Madsen TM, Johnson K: A phase II trial of an adenovirus/PSA vaccine for prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of an adenovirus/PSA vaccine for prostate cancer.
  • : 3065 Background: Our phase I adenovirus/PSA vaccine trial has proven the vaccine is safe.
  • We are conducting a phase II clinical trial with two separate protocols for patients with recurrent or hormone-refractory prostate cancer assessing toxicity, immune responses, and change in PSA levels.
  • Each injection consists of 108 pfu of Ad/PSA vaccine suspended in a collagen matrix.
  • Median patient age is 70 years (range 61-84), and median enrollment PSA levels are 0.79 ng/ml (range 0.24-3.93) in Protocol 1 and 5.47 ng/ml (range 0.29-11.17) in Protocol 2.
  • Preliminary results show 86% in both protocols demonstrating anti-PSA T cell responses above preinjection levels.
  • 25% have stable serum PSA levels, 50% have decreased levels, and 25% have increased levels.
  • 11% have stable serum prostatic acid phosphatase (PAP) levels, 56% have decreased levels, and 33% have increased levels.
  • CONCLUSIONS: These early results from the first few months of this phase II trial demonstrate the induction of anti-PSA T-cell responses in a high percentage of the vaccinated patients and stabilization or declines in serum PSA and PAP levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962013.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG: A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5156

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility requirements include progressive measurable disease or rising PSA levels after antiandrogen withdrawal and < 2 prior chemotherapy regimens.
  • Pts were given prednisone 5 mg po |[BI]D continuously and 8 mg of decadron 12, 8 and 1 hour prior to D without prophylactic anticoagulation.
  • Pt characteristics include median age of 70 yrs (range 47-85), median baseline PSA of 101.9 ng/ml (range 5.9-7480), 14 pts (41%) had received prior chemotherapy (7 with 2 prior regimens).
  • Other Grade 3/4 toxicities observed after cycle 1 included deep venous thrombosis (2 pts), grade 3 neutropenia (2 pts), grade 3 facial edema (1 pt) Of 31 pts evaluable for post treatment PSA declines; 8/17 (47%) untreated pts 7/14 (50%) previoustly treated pts had a >50% decline in PSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D: Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological evidence of adenocarcinoma of the prostate was required with clinical stage T<sub>1c</sub> or T<sub>2a</sub> with Gleason 8-10 disease, or clinical stage T<sub>2b</sub>-T<sub>2c</sub> with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T<sub>3</sub>.
  • Cytopathic effects (cytolysis, nuclear pyknosis) were commonly seen compared to baseline tumor.
  • Two of 8 evaluable patients had a >50% decrease in serum PSA with bortezomib treatment; 3 others had PSA declines of 14%, 25%, and 45%, respectively; 1 patient had no change, and 2 displayed PSA increases.
  • A comprehensive toxicity analysis will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Vaishampayan UN, Heilbrun LK, Heath EI, Smith DW, Dickow B, Baranowski K, Powell I, Fontana J: Phase II trial of bevacizumab (B) and oral satraplatin (S) and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoint was time to progression defined as a skeletal event, new areas of metastases on bone scans or per RECIST criteria for measurable disease.
  • RESULTS: 19 of 28 patients have been enrolled to date; 7 African American and 12 Caucasian,, with median age of 68.5 years and median pretherapy PSA of 137.8 ng/mL (range 16.8-994 ng/mL).
  • Measurable disease progression was noted in 5 patients, bone scan progression in 6 patients, progression of both in 3 patients, and PSA only progression in 5 patients.
  • 7 patients had a PSA decline of which 4 patients had a ≥30% PSA decline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962967.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Scher HI, Beer TM, Higano CS, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Fleisher M, Prostate Cancer Clinical Trials Consortium: Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor activity of MDV3100 in a Phase I/II trial was assessed by prostate-specific antigen (PSA), soft tissue and osseous disease, circulating tumor cells (CTC), and time on treatment.
  • PSA declines (>50% from baseline) were observed at week 12 in 57% (37/65) of naïve and 45% (22/49) of post-chemo pts.
  • Data suggest a dose-response trend particularly in post-chemo pts where PSA responses were 32% at 60 and 150 mg/day and 58% at 240 and 360 mg/day.
  • CONCLUSIONS: MDV3100 is a promising candidate for the treatment of prostate cancer assessed by PSA, imaging, CTC, and time on treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962905.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Glode LM, Tangen CM, Hussain MH, Wood DP Jr, Swanson GP, Quinn DI, Dawson N, Balzer-Haas N, Crawford ED, Thompson IM: Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. J Clin Oncol; 2009 May 20;27(15_suppl):5009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DSMC has approved this analysis.
  • PSA was to be assessed every 3 mo for 5 yrs and then every 6 mo for 10 more yrs.
  • PSA relapse was defined as 3 consecutive measurements > 0.2 ng/ml.
  • Risk groups based on eligibility criteria are as follows: Risk Group 1= positive margins or extraprostatic extension only with Gleason 7; elevated PSA (pre-op > 15 ng/ml), or had a pre-op PSA > 10 ng/ml and a biopsy Gleason 7(N=113); Risk Group 2 = seminal vesicle invasion or Gleason >/= 8, but no positive nodes (N=240), Risk Group 3 =positive nodes (N=69), 397 patients from both arms who completed 2 years of CAB were assessed for time to testosterone (T) recovery.
  • CONCLUSIONS: These data indicate a markedly low PSA relapse and death rates in high risk PC patients who received CAB.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962889.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Noguchi M, Uemura H, Kumon H, Nasu Y, Hirao Y, Matsuoka K, Kakuma T, Yamada A, Itoh K: A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients with hormone-refractory prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This randomized study evaluated the anti-tumor effect and safety of PPV plus a low-dose EMP compared with full dose EMP for patients with hormone-refractory prostate cancer (HRPC).
  • Pts were randomized to arm A; PPV plus low-dose EMP (280 mg/day) or arm B; full dose EMP (560 mg/day) according to age and PSA levels.
  • Disease progression (PD) was defined as three consecutive and 125% increase from baseline PSA levels at least two weeks apart or objective PD by RECIST criteria.
  • The main pts characteristics are (arm A/B): median age 71/69 years, EOCG performance status 0/1 96%/4% and 100%/0%, HLA A2/A24/A2A24 40%/32%/28% and 54%/27%/19%, median PSA 27/25 ng/ml, and metastatic HRPC 96%/85%.
  • All pts were evaluable for their response at the time of interim analysis.
  • CONCLUSIONS: PPV plus low-dose EMP was associated with improvement in PSA-based PFS compared to full-dose EMP alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962045.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Hoffman KE, D'Amico AV: Prostate cancer screening practice among men age 75 and older: Results from a national survey. J Clin Oncol; 2009 May 20;27(15_suppl):e16034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluated the use of prostate specific antigen (PSA) screening among men age 75 and older prior to this declaration.
  • Univariable and multivariable logistic regression was used to determine factors associated with PSA screening.
  • More than half (51.6%) underwent PSA screening within the previous two years.
  • Men who reported poor health status (42.2 vs. 55.2%, p=0.005) and men who had difficulty with at least one IADL (37.4 vs. 53.3%, p=0.010) were less likely to have a screening PSA.
  • After adjustment for age, race, education status, and physician access, poor health status (adjusted odds (AOR): 0.70, 95% CI (CI): 0.45 to 1.10; p = 0.119), two or more significant diseases (AOR: 0.78, CI: 0.48 to 1.27; p = 0.333) and difficulty with at least one IADL (AOR: 0.71, CI: 0.42, 1.20; p = 0.202) were not associated with the use of PSA screening.
  • Of the 104 men likely to live for five years or less because of poor health, 35.0% underwent PSA screening.
  • CONCLUSIONS: Health status, a predictor of life expectancy, should be considered when determining which men receive PSA screening.
  • This would reduce the use of PSA screening in men unlikely to benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ryan C, Efstathiou E, Smith M, Taplin M, Bubley G, Logothetis C, Kheoh T, Haqq C, Molina A, Small EJ: Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol; 2009 May 20;27(15_suppl):5046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Results: At baseline median age was 71.0 (range 52-85) yrs and median PSA was 24.7 (range 7.1-1110.0) ng/mL;19/26 pts (73%) had an ECOG PS of 0 and 7/26 (27%) had PS of 1; the median number of prior hormonal therapies was 2; all pts were on LHRHa and 73% of pts had received anti-androgen, all of whom had undergone prior anti-androgen withdrawal.
  • Pts were evaluated at each cycle for PSA response according to PSAWG criteria.
  • 27 pts have available data for PSA response.
  • Total maximal PSA declines of ≥30%, ≥50%, ≥90% were observed in 89% (24/27), 85% (23/27) and 41% (11/27) pts, respectively.
  • Week 12 PSA declines displayed a similar and sustained trend: ≥30%, ≥50% and ≥90% PSA decline in 82%, 78%, and 26% of pts.
  • Post-treatment ECOG PS score was 0 in 24 (92%) pts: 19% experienced improvement in PS (PS 1 to 0 in 5 pts) and 19/19 pts maintained a PS of 0; Median time to PSA progression has not been reached.
  • CONCLUSIONS: Abiraterone acetate plus prednisone has significant anti-cancer activity in patients with metastatic CRPC not previously treated with ketoconazole or chemotherapy, as demonstrated by declines in PSA and improvement in performance status, and is well-tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962951.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, Chester J, Wallace DM, Doherty A, Leung H, Young LS, James ND: A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984. Mol Ther; 2009 Jul;17(7):1292-1299

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : We report a phase I/II clinical trial in prostate cancer (PCa) using direct intraprostatic injection of a replication defective adenovirus vector (CTL102) encoding bacterial nitroreductase (NTR) in conjunction with systemic prodrug CB1954.
  • Based on acceptable safety data and indications of prostate-specific antigen (PSA) responses, an extended cohort received virus at a single dose level plus prodrug.
  • Immunohistochemistry of resected prostate demonstrated NTR staining in tumor and glandular epithelium at all dose levels [5 × 10<sup>10</sup>-1 × 10<sup>12</sup> virus particles (vp)].
  • A total of 19 patients received virus plus prodrug and 14 of these had a repeat treatment; minimal toxicity was observed and there was preliminary evidence of change in PSA kinetics, with an increase in the time to 10% PSA progression in 6 out of 18 patients at 6 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178475.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Prins R, Rademacher BL, Mongoue-Tchokote S, Eilers KM, Beer TM: C-reactive protein as adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. J Clin Oncol; 2009 May 20;27(15_suppl):5168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5168 Background: We previously reported that higher serum concentrations of C-reactive protein (CRP) are associated with shorter survival in men with metastatic CRPC treated with docetaxel-containing chemotherapy.
  • 91% of patients had metastases and 9% had PSA-only disease.
  • In addition to CRP, we examined alkaline phosphatase, hemoglobin, age, ECOG PS, and PSA collected at study entry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Mardjuadi F, Medioni J, Kerger J, Canon JL, Duck L, Oudard S, Clausse M, D'Hondt L, Moxhon A, Machiels JP: A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5153

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PK analysis showed that mean C<sub>max</sub> and AUC of D were increased at cycle 2 in cohort 2, 3, and 4 indicating a PK interaction dependent on the exposure to S.
  • PSA response (> 50% in PSA decrease) was recorded in 15 out of 20 pts.
  • PK analysis revealed an interaction between D and S that may explain the high rate of febrile neutropenia and Gr4 neutropenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964477.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Gernone A, Pagliarulo V, Trabucco S: Prognostic role of somatostatin receptor subtypes in human prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NED of PC correlates with poor prognosis and tumor progression during androgen-deprivation therapy.
  • Patient characteristics included: median age 68 years (range 45-83), median baseline PSA: 70 ng/ml (range 0.3-200), median ECOG Performance Status: 1 (range 0-2), Gleason score ≥ 7, medium serum level of CgA was 56.2 nmol/L (range 0.5-120).
  • The PSA and CgA levels were not correlated with clinical outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA: A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):5135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: PCa pts with PSA doubling time (PSADT) of < 12 months, no radiographic evidence of metastasis, no hormonal therapy within 6 months were enrolled.
  • PSA progression was defined as at least a 50% increase in PSA and >5 ng/mL increase from baseline or post-treatment nadir and confirmed.
  • Endpoints included the proportion of pts who did not have PSA progression for 24 weeks, change in PSA slope/PSADT, and assessment of safety and tolerability.
  • Fourteen of 27 (52%) in the low dose and 6/25 (24%) in the high dose cohort were PSA progression free for 24 weeks.
  • One patient in high dose cohort showed PSA >50% decrease of 40 days duration.
  • Pre- and on-treatment PSA kinetics are shown below.
  • CONCLUSIONS: ATN-224 may have biologic activity in men with androgen-dependent PCa at low doses, as demonstrated by > 50% of pts being PSA progression free at 6 month and a significant decrease in mean PSA slope.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Armstrong AJ, Halabi S, Tannock IF, George DJ, DeWit R, Eisenberger M: Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. J Clin Oncol; 2009 May 20;27(15_suppl):5137

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5137 Background: Our aim was to develop and validate clinically applicable predictive factors for a >30% PSA decline 3 months following chemotherapy initiation, and to assess the performance of a risk-group based classification in predicting PSA declines and overall survival (OS) in men receiving chemotherapy for mCRPC.
  • METHODS: In TAX327, 1006 men with mCRPC were randomized to receive docetaxel (D) in two schedules, or mitoxantrone (M), each with prednisone: 989 provided data on PSA decline at 3 months.
  • Predictive factors for a >30% 3-month decline in PSA levels were identified using multivariate logistic regression in D treated men (n = 656) and validated in M treated men (n = 333).
  • Risk factors were combined to form risk groups to predict PSA declines, OS, tumor, and pain responses.
  • RESULTS: In multivariate analysis, four independent risk factors predicted for absence of >30% decline in 3-month PSA: significant baseline pain (OR 0.63 p = 0.02), visceral metastases (OR 0.66, p = 0.03), anemia (hemoglobin <13 g/dl, OR 0.72 p = 0.07), and bone scan progression at baseline (OR 0.60 p = 0.009).
  • Risk groups (good, intermediate, poor) were developed with median OS of 25.7 (95% CI 23.3-28.6), 18.7 (17.3-19.7), and 12.8 (11.5-14.6) months, respectively (p < 0.0001), and >30% PSA decline in 78, 66, and 58 percent of men (p < 0.001).
  • In the validation M cohort, similar trends for PSA declines and OS were noted across risk groups (OS 22.5, 16.0, 11.8 mo, p < 0.001).
  • CONCLUSIONS: Risk groups have been identified and internally validated that predict PSA decline and OS in men with mCRPC.
  • This classification may facilitate evaluation of new regimens of systemic therapy that warrant definitive testing in comparison to docetaxel and prednisone in phase III trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Cetnar JP, Rosen MA, Vaughn DJ, Haas NB, Troxel AB, Song H, Adluru G, Flaherty KT, O'Dwyer PJ, Amaravadi RK: Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16055 Background: Previous trials of the antiangiogenic kinase inhibitor sorafenib in mCRPC have reported PSA elevation accompanying radiographic response, and evidence that sorafenib may potentiate docetaxel (dxl) myelosuppression.
  • The primary endpoint was PSA response rate (>50% PSA decline).
  • Secondary endpoints were vascular response rate (>20% decline in area under the gadolinium curve [AUC60]), toxicity rates, and time to progression (TTP).
  • PSA-only progression (2 consecutive PSA rises) was confirmed by a third PSA rise or radiographic progression after a 21-day drug holiday.
  • RESULTS: Six of 13 enrolled patients (46%) had a PSA response.
  • A median PSA increase of 37% was observed in 73% of patients after 1 week of sorafenib.
  • Elevated PSA values in men treated with sorafenib and dxl does not always reflect disease progression.
  • DCE-MRI can capture sorafenib's impairment of tumor vasculature in osseous metastases and rebound angiogenesis during drug holidays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E, National Cancer Institute of Canada Clinical Trials Group: Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoint was PSA response rate (RR).
  • Planned sample size was 40/arm: Arm A the hypotheses (PSA RR<40% vs. >60%) could be tested at 10% β and 10% α, Arm B the true PSA RR could be estimated with half-width of the 90% CI<13% if PSA RR=40%.
  • At this analysis time, all pts are off therapy and 49 have died.
  • One pt was ineligible but included in ITT survival analysis.
  • Baseline characteristics were similar: median age 69 (49-87), PSA >100 μg/L in 51%, Hgb ≥100 g/L in 98%, alk phos >ULN in 44%, LDH >ULN in 36%, ECOG performance status (PS) 0:1 in 51%:49%, bone/lymph node/visceral metastases in 69%/50%/28%.
  • Mean serum clusterin change on day 1 cycle 2 was -18% in Arm A and +8% in Arm B (p = 0.0005).
  • PSA RR was 58% (Arm A) and 54% (Arm B).
  • PSA declines at 12 weeks of any/>30%/>50% was observed in 87%/65%/45% (Arm A) and 68%/58%/34% (Arm B).
  • PSA/objective disease progression as best response occurred in 0%/4% (Arm A), and 3%/17% (Arm B).
  • Variables predictive of OS on multivariate analysis: PS 0 vs 1 (p = 0.0002), presence of visceral metastasis (p = 0.006) and treatment assignment (HR = 0.54 [0.29-0.97], p = 0.04).
  • CONCLUSIONS: The PSA RR in both arms met criterion for further study.
  • OGX reduced serum clusterin and OS appears superior with DOC/OGX.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Pinski JK, Goldman B, Dorff T, Mack P, Lara P Jr, van Veldhuizen P, Quinn D, Hussain MH, Thompson IM: SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration- resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoint was PSA response rate (RR) defined as ≥50% reduction.
  • Two (3.7%; 95% CI: 0.5%, 12.8%) had PSA response.
  • CONCLUSIONS: CNTO328 was well-tolerated and resulted in a PSA RR of 3.7% and RECIST SD rate of 21%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Lee RJ, Stott SL, Nagrath S, Ulkus LE, Dahl DM, Smith MR, Toner M, Maheswaran S, Haber DA: Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using the CTC-chip microfluidic device. J Clin Oncol; 2009 May 20;27(15_suppl):5149

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using the CTC-chip microfluidic device.
  • In localized disease, CTCs may be indicative of tumor invasiveness.
  • Molecular analyses of CTCs through this minimally invasive technique may provide insights into disease behavior, whereas sampling of metastatic deposits in bone (the predominant site of prostate metastasis) is not feasible.
  • Quantities were determined using cytokeratin- and PSA-based staining and enumeration.
  • In some cases, molecular analyses for the TMPRSS2:ERG chromosomal translocation were performed using FISH in intact cells or nuclei, or RT-PCR in extracted RNA.
  • RESULTS: PSA-stained CTCs were captured in all patients.
  • In patients with metastatic disease undergoing either ADT or chemotherapy, CTC quantities generally corresponded with changes in serum PSA and radiographic assessments.
  • CONCLUSIONS: These studies are the first to use the highly sensitive CTC-Chip technology to assess dynamic changes in CTCs in patients undergoing prostatectomy, ADT, or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Nozawa M, Yoshida M, Saito Y, Nakagawa M, Ozeki T, Yoshikawa M, Aono Y, Uemura H: Serum selenium and risk of prostate cancer in Japanese men. J Clin Oncol; 2009 May 20;27(15_suppl):e16166

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum selenium and risk of prostate cancer in Japanese men.
  • We examined the association between serum selenium levels and risk of prostate cancer in men who received a prostate biopsy in our hospital.
  • METHODS: Our prospective study included 82 patients who received a prostate biopsy based on elevated PSA levels over 4.0ng/ml.
  • Serum from each patient was sampled to determine the selenium level at the time of biopsy.
  • RESULTS: The mean serum selenium levels in the case and control group were 120.4 (SD, 14.4) ng/mL and 118.5 (SD, 16.1) ng/mL, respectively (p = 0.588).
  • Serum selenium levels at biopsy were not associated with risk of prostate cancer diagnosis.
  • In the case group, the mean serum selenium levels in patients diagnosed with 6 or less in Gleason score and 7 or more were 121.0 (SD, 9.9) ng/mL (n = 14) and 120.1 (SD, 16.1) ng/mL (n = 33), respectively (p = 0.851).
  • Serum selenium levels at biopsy were not associated with Gleason score in the case group.
  • An inverse association between serum selenium and PSA levels at biopsy was observed (p = 0.030).
  • No correlation was observed between serum selenium level and age at biopsy.
  • CONCLUSIONS: From this study, serum selenium level cannot predict the result of prostate biopsy.
  • The inverse association between serum selenium and PSA levels may suggest that low selenium levels are associated with an increased incidence of prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Stephenson AJ, Klein EA, Kattan MW, Han M, Partin AW, Walsh PC, Trock BJ, Wood DP, Eggener SE, Eastham JA, Scardino PT: Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. J Clin Oncol; 2009 May 20;27(15_suppl):5007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5007 Background: Nomograms that predict prostate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate cancer after radical prostatectomy are the most widely used prediction tools in oncology for treatment decision making and counseling.
  • METHODS: Using Fine and Gray competing risk regression analysis, the clinical data and follow-up information of 11,521 patients treated with radical prostatectomy at four academic centers from 1987 to 2005 were modeled to predict PCSM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kolevska T, Ryan CJ, Huey V, Weisberg L, Wang S, Baer D, Ghadialy A, Goldstein D, Fireman B, Fehrenbacher L: Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5152

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nab-paclitaxel, an albumin-bound nanopaticle form of paclitaxel, delivers paclitaxel without steroids, requires only 30 minutes infusion time and has favorable toxicity profile that may be more tolerable but effective in patients with prostate cancer.
  • Primary endpoint was efficacy based on prostate-specific antigen (PSA) response.
  • PSA response was PSA decrease of >50%, progressive disease (PD) was PSA increase of >25%, stable disease (SD) was <25% PSA increase or <50% decrease sustained longer that 8 weeks.
  • PSA response was seen in 9 (25%) patients and SD in 15 patients (43%), with an overall response rate of 25% and clinical benefit of 68%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964449.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Gómez-Pinillos A, Ballard H, Shelton G, Reilly MM, Chachoua A, Taneja S, Ferrari AC: Sequential and intermittent docetaxel (D) and imatinib (Im) in hormone-refractory prostate cancer patients (NYU 04-47). J Clin Oncol; 2009 May 20;27(15_suppl):e16108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sequential block of the cell cycle progression in G2-M followed by G1-S may increase anti-tumor responses.
  • METHODS: Eligibility: at least 2 prior hormone manipulations and up to one prior chemotherapy, PSA>5ng/ml, ECOG PS 0-2.
  • A two steps design was planned to assess activity (PSA decline >50% and/or measurable or symptomatic response) and tolerance including interim analysis to determine if 37 patients (pts) should be enrolled.
  • There were 98 cycles of trial therapy administered and 9 events (PSA or bone progression) registered at the time of analysis.
  • Median baseline PSA 73,5ng/ml (2.1-1954.3).
  • PSA decline >50% observed in 7/15pts (46.67%) of which 3 was >80% (20%).
  • PSA decline <50%, observed in 6/15(40%).
  • CONCLUSIONS: Sequential and intermittent D every 21 days and Im for 14 days is tolerable and active by PSA decline and symptomatic improvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963331.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Oh WK, Febbo PG, Richie JP, Fennessy FM, Scibelli G, Hayes JH, Choueiri TK, Tempany CM, Taplin ME, Ross RW: A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):5060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility included any of the following: PSA > 20 ng/ml or PSA velocity > 2 ng/ml/yr, cT3 disease, any biopsy Gleason 8-10, Gleason 7 with T3 disease by endorectal (er) MRI.
  • Also, >50% biopsy cores involved and either Gleason 7 or PSA >10 or cT2 disease were eligible.
  • The primary endpoint was erMRI partial response (PR, defined here as >50% decrease in tumor volume) in a single target lesion after chemotherapy.
  • Median PSA was 10.5 ng/ml (range 2.1-72.5).
  • Of 23 evaluable pts to date, the median decline in the maximal tumor volume by erMRI was -45% (range -84% to 110%).
  • Any PSA decline was noted in 22/34 (65%) evaluable pts, with 18% having a >50% decline.
  • Only 1 pt stopped treatment because of a rising PSA.
  • CONCLUSIONS: Neoadjuvant docetaxel and bevacizumab demonstrates clinical evidence of activity in men with high-risk localized prostate cancer, with a 39% PR rate by erMRI and PSA declines noted in 65%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Luu T, Sartor O, Dandade N, Halabi S, Bennett C: Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry. J Clin Oncol; 2009 May 20;27(15_suppl):5131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry.
  • : 5131 Background: HT may lower PSA, but it may also cause hot flashes and sexual dysfunction.
  • OBS is not associated with hot flashes or lower testosterone production, but PSA may rise.
  • METHODS: The Comprehensive Multicenter Prostate Adenocarcinoma Registry (COMPARE) is an observational registry of men with PSA failure.
  • The median time between cancer diagnosis and registry enrollment was 6 years.
  • CONCLUSIONS: Men with PSA failure seem content with treatment choice and decision making and have low rates of urinary/bowel problems.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964431.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Sinibaldi VJ, Carducci MA, Moore-Cooper S, George B, Denmeade S, Drake CG, Walczak J, Pili R, Zahurak ML, Eisenberger MA: A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M&lt;sub&gt;0&lt;/sub&gt;) after local treatment (LT). J Clin Oncol; 2009 May 20;27(15_suppl):5130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligible pts had: rising PSA (≥1 ng/mL), M<sub>0</sub> disease, testosterone > 150 ng/mL, adequate bone marrow, renal, and hepatic function.
  • Baseline and Q 2 mos PSA's were processed after Q 6 mos of L, along with CT and bone scan.
  • Primary endpoints are safety and progression after 6 mo of L (defined by a confirmed ↑ in PSA > 25% over the baseline value or mets).
  • Secondary endpoints are changes of slopes in PSA related to pharmacokinetics (pk).
  • A sample size of 30 pts/arm provides an 85% power to detect a PSA progression rate of 40% (compared to 80% predicted ) with a Type I error = 0.05 (Fishers exact test).
  • Pooled data from the 2 arms: median: age 64 (50-81), ECOG PS 0, baseline PSA 9.3 ng/ml (1.3-92.8 ng/ml).
  • Of 44 pts, blinded evaluation of PSA's at 6 mos: 4 pts had ≥ 50% ↓, 22 had stable PSA,17 had PD, 1 too early .
  • CONCLUSIONS: Preliminary data prior to unblinding the study treatment arms, from pooled data, suggest that L may be administered > 6 mos with acceptable toxicity, and is associated with PSA declines and long term stabilization in pts with BR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964411.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Chi D, Hirsch AE, Gignac GA: Biochemical failure after radiation therapy for prostate cancer: Racial differences. J Clin Oncol; 2009 May 20;27(15_suppl):e16071

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The generalizability of these results assumes similar tumor biology among all races.
  • We set out to examine biochemical failure (PSA failure) rates in a cohort of pts after definitive external beam radiation (EBRT) in the racially diverse population at our institution.
  • We excluded from analysis pts who received brachytherapy, salvage, adjuvant or palliative radiation.
  • Race, country of origin, diagnostic data, pre- and post-treatment PSA, Gleason score (GS), clinical stage (CS), and treatment history were reviewed.
  • CS was based on the original clinician's assessment at time of diagnosis.
  • PSA failures were defined using 1996 ASTRO criteria.
  • Statistical analysis was performed using Fisher's Exact test.
  • The white cohort had a high proportion of pts with a pretreatment PSA <10 ng/ml (66%) as compared to the nonwhite cohort (46%).
  • PSA failure rate was 7% for the white cohort and 13% for nonwhite (p = 0.41).
  • CONCLUSIONS: In this retrospective analysis, there was no statistical difference among races with regard to PSA failure rates.
  • The PSA and Gleason trends in each cohort were consistent with published data on this topic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963037.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Mohebtash M, Madan RA, Arlen PM, Rauckhorst M, Tsang KY, Cereda V, Vergati M, Poole DJ, Dahut WL, Schlom J, Gulley JL: Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5144

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
  • PSA-TRICOM V is composed of poxviral vectors encoding PSA and 3 costimulatory molecules (ICAM-I, LFA-3, and B7.1) and has clinical activity in mCRPC.
  • Ipi blocks CTLA-4, a T-cell downregulatory receptor, has clinical activity in mCRPC as monotherapy and has also been shown to enhance anti-tumor responses in combination with V in preclinical studies.
  • Median PSA doubling time (DT) ↑ from 2.2 mo at baseline to 3.7 on study (p = 0.17).
  • 5 of 9 had ≥ 50% ↓ in PSA from peak during study and 1 had a sustained ↓ PSA > 95% from baseline.
  • 1 had a sustained ↓ in PSA > 99% from baseline and is still on study after 12 mo.
  • Median PSA DT ↑ > 3-fold from 2.6 mo at baseline to 8.2 on study (p = 0.01) in DL4.
  • The 24 chemo-naïve pts had PSA DT ↑ from 2.5 to 6 mo (p = 0.003).
  • 14 of 30 pts had a PSA ↓ from baseline or peak PSA on study.
  • 2 of 14 had no irAE, 12 showed ≥ G2 irAE temporally associated with PSA ↓.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964446.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Antonarakis ES, Trock BJ, Feng Z, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA: The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):5008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up.
  • : 5008 Background: In men with prostate specific antigen (PSA) recurrence following radical prostatectomy (RP) and no other therapy, the natural history of metastatic progression was previously described in 1999.
  • METHODS: We performed a retrospective analysis of 774 men treated with RP between 4/1982 and 7/2008 who developed PSA recurrence (>0.2 ng/ml) and never received adjuvant or salvage therapy.
  • Of 774 men with PSA recurrence, 295 (38%) developed metastases, and 433 had data on PSA doubling time (PSADT), forming our cohort.
  • The mean time from RP to PSA recurrence in the entire cohort was 4.2 y (median 3 y).
  • In those who developed metastases, the mean time from PSA recurrence to metastasis was 3.1 y (median 2 y).
  • The mean PSA at the time of metastasis was 90.3 ng/ml (median 31.4 ng/ml).
  • In Cox regression analysis: PSADT, Gleason score, and time to PSA progression were predictive of the development of metastases ( Table ).
  • In Kaplan-Meier survival analysis, the median actuarial time from PSA recurrence to metastasis was 10 y (95% CI 9 - 15 y).
  • Median actuarial metastasis-free survival from PSA recurrence for men with PSADT <3 mo, 3 - 8.9 mo, 9 - 14.9 mo, and >15 mo was 1 y (95% CI 0 - 1 y), 4 y (95% CI 2 - 6 y), 9 y (95% CI 7 - 13 y), and 15 y (95% CI 12 - 20 y), respectively.
  • CONCLUSIONS: PSADT, Gleason score, and time to PSA progression are strong independent predictors of metastasis-free survival in men with PSA-recurrent prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Hayes JH, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV: Short-course androgen suppression therapy prior to brachytherapy for favorable-risk prostate cancer and the risk of all-cause mortality in men with or without preexisting cardiovascular disease. J Clin Oncol; 2009 May 20;27(15_suppl):5066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study cohort included 12,792 men with previously-untreated low or intermediate risk prostate cancer (PSA < 20 ng/mL; Gleason score 7 or below on initial biopsy; clinical category T2c or below) treated between 1992 and 2005 at one of 21 community-based medical centers in Illinois, Florida, New York, or North Carolina.
  • Multivariate Cox regression analysis was performed to assess whether significant associations between preexisting CVD and ACM existed adjusting for age, year of treatment and known prostate cancer prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964251.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Eisinger F, Morere J, Pivot X, Blay J, Coscas Y, Calazel Benque A, Roussel C, Viguier J: Trends in screening for prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In France, there is no financial barrier for individuals to be screened with the prostate-specific antigen (PSA) test, and there is no recommendation for mass screening.
  • RESULTS: General population: In 2005, 36% of the interviewed male population aged between 50 and 75 years declared having undergone a screening test, compared to 49% in 2008 (OR = 1.63 CI<sub>95%</sub> 1.25; 2.12).
  • Prostate cancer screening increased in all age groups, however, the most significant increase can be observed in the population aged between 50 and 54 years: 18% in 2005 versus 35% in 2008 (OR = 2.43 CI<sub>95%</sub> 1.31; 4.52).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Kunitake H, Zheng P, Yothers G, Land S, Fehrenbacher L, Giguere JK, Wickerham DL, Ganz PA, Ko CY: Routine preventive care and cancer surveillance in long-term survivors (LTS) of colorectal cancer: Results from NSABP Protocol LTS-01. J Clin Oncol; 2009 May 20;27(15_suppl):6500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LTS-01 patients were more likely to have received a flu shot in the past 12 months (68% vs. 42%, p < 0.0001) and were also more likely to have undergone cancer screening by Pap smear (67% vs. 54%, p < 0.001), mammogram (85% vs. 71%, p < 0.001), and PSA test (84% vs. 75%, p < 0.001).
  • CONCLUSIONS: Long-term survivors of colorectal cancer achieve better routine preventive care including cancer screening than the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Koolen S, Witteveen PO, Garcia-Ribas I, Callies S, Andre V, Kronemeijer RH, Nol A, Beijnen JH, Voest EE, Schellens JH: Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One pt with refractory prostate cancer presented a PSA CR as assessed by investigator.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961892.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Stein MN, Knox B, Wesolowsky E, Levitt M, Moss R, Poplin E, Mehnert J, Gounder M, Goodin S, DiPaola R: Phase I trial of patupilone (P) and RAD001 in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 24 pts have been enrolled and 23 pts are evaluable for toxicity (tumor types: colon-7, prostate-6, lung-3, ampulla-3, leiomyosarcoma-2, cervical cancer-1).
  • In pts with prostate cancer (all previously pretreated with D) PSA declines of >50% occurred in 3/5 pts treated with >2 cycles; 1/7 pts with colon cancer had a PR and 3/7 pts with colon cancer had stable disease (SD) > 8 cycles; 1/3 pts with ampullary ca had a PR and a pt with cervical ca had SD x10 cycles.
  • Encouraging evidence of clinical activity is observed in prostate, colon and other tumor types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A: Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3511 Background: Src kinase is central to the proliferation, apoptosis and metastasis of tumor cells.
  • KX2-391 has a much wider spectrum of solid tumor activity in vitro, and is more potent in mouse xenografts, as compared to other multikinase Src/Abl inhibitors.
  • Both the prostate and pancreatic cancer pts had dramatic decreases in their biomarkers (PSA went from 205 ng/ml to 39 ng/ml, and CA19-9 went from 38,838 U/ml to 267 U/ml, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Lo Re G, Boccalon M, Maruzzi D, Bortolus R, Lenardon O, Marus V, Rustici C, Tumolo S, Garbeglio A, Sulfaro S: A phase II noncomparative study of neoadjuvant (NA) chemohormone therapy (CHT), radical prostatectomy (RP), and postoperative radiotherapy (RT) in locally advanced (LA) high-risk prostate cancer (HRPC): A monoinstitutional 6-year experience with two NA CHT regimens. J Clin Oncol; 2009 May 20;27(15_suppl):e16091

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16091 Background: HRPC criteria include stage T2b-T2c according to the AJCC classification, PSA ≥ 10 ng/ml, Gleason score (GS) 7-10 with 12, 6% 7-year cancer specific mortality rate (D'Amico AV, Cancer. 2006).
  • METHODS: Histological diagnosis of LA HRPC (T2b-T4), GS > 8, PSA > 10 ng/ml, age < 65 years, PS 0-1.
  • Primary endpoint: disease-free survival (DFS); secondary endpoint: PSA relapse-free survival (RFS), overall survival (OS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Turner JS, Chen CS, Butler W, Bearden J 3rd, Garrett-Mayer E, Onicescu G, Kraft AS: Bortezomib therapy for prostate specific antigen (PSA)-only relapse after definitive local therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib therapy for prostate specific antigen (PSA)-only relapse after definitive local therapy.
  • : e16053 Background: We conducted a single arm, phase II trial of single-agent bortezomib, a proteasome inhibitor, in patients with prostate cancer with biochemical recurrence (PSA relapse) after definitive local therapy.
  • Eligible patients had previous radical prostatectomy and/or radiation therapy (including brachytherapy), and a rising PSA over 1 ng/mL without bone scan evidence of metastasis.
  • The primary goal of this study was to determine the PSA response to single agent bortezomib.
  • Secondary goal was to identify the time to PSA relapse after bortezomib therapy defined as time from nadir to PSA >1ng/ml.
  • RESULTS: Median baseline PSA was 12.0 ng/ml.
  • Median time to PSA relapse in these 3 patients was 6.0 months.
  • Linear longitudinal modeling was used to compare the rate of increase in PSA prior to treatment versus during treatment with bortezomib and found that treatment significantly decreased the slope of log PSA during treatment, slowing PSA rise (p = 0.003).
  • CONCLUSIONS: In a small number of patients there was a 30% PSA response rate to single agent bortezomib therapy.
  • Further investigations using bortezomib as a single-agent or in combination are warranted in this patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963004.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Donato Di Paola E, Alonso S, D'Alessio A, Giuliani R, Calabrò F, Messina C, Zivi A, Squilloni E, De Marco S, Sternberg C: Dose finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2 pts had PSA declines, with TTP of 630 days in 1 of them.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hotte SJ, Yu EY, Hirte HW, Higano CS, Gleave M, Chi KN: OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. J Clin Oncol; 2009 May 20;27(15_suppl):3506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Circulating tumor cells (CTC), Hsp27+ CTC and serum Hsp27 levels were evaluated serially.
  • Three pts with prostate ca had PSA declines of 43%, 58%, 62% and 3 pts with ovarian cancer had CA-125 declines of 27%, 28%, and 41%.
  • Changes in tumor markers suggest single-agent activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Bylow KA, Hemmerich J, Mohile S, Stadler W, Dale W: Abnormal physical performance and frailty in older men with biochemical recurrence of prostate cancer (PCa) on androgen deprivation therapy (ADT). J Clin Oncol; 2009 May 20;27(15_suppl):e20578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A case-control study (n=119) of men age 65+ with BCR on ADT ≥ 6 months with stable PSA (n=56) compared to controls with history of PCa status post radiation or surgery with no evidence of recurrence (n=63) was conducted.
  • Exploratory analyses of proposed biomarkers of frailty (CRP, ESR, hemoglobin, albumin, and total cholesterol) were conducted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961100.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Rademacher BL, Garzotto M, Higano CS, O'Brien CA, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM: Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5121 Background: Efforts to incorporate systemic therapy with activity against castration-resistant prostate cancer into the early management of high-risk disease are motivated by persistent risk of relapse when neoadjuvant androgen suppression therapy (AST) is combined with surgery.
  • As docetaxel and mitoxantrone exert anti-tumor effects through distinct cellular mechanisms, this combination has the potential for synergistic activity against prostate cancer.
  • Relapse was defined as a confirmed serum PSA > 0.4 ng/mL.
  • Serum testosterone levels remained stable after chemotherapy.
  • Pretreatment serum PSA, lymph node involvement, and post-chemotherapy tissue VEGF expression were independent predictors of early relapse.
  • Approximately half of the high risk pts remain relapse free at 5 years and clinical and molecular predictors of early relapse in this population have been identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964409.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Hatcher D, Rose AE, Christos PJ, Mazumdar M, John M, Taneja SS, Lee P, Osman I: Impact of race on survival of prostate cancer patients treated with noncurative intent. J Clin Oncol; 2009 May 20;27(15_suppl):5069

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2) no evidence of metastatic disease within 6 months after diagnosis;.
  • AA men presented with significantly higher PSA compared to CA patients (median 18.5 versus 11.4 respectively, p = 0.004), however, there were no differences in age at presentation (median 73 versus 74, p = 0.98) or Gleason score (23% of AA and CA had Gleason >7, p = 0.92).
  • Factors most predictive of mortality by Cox regression multivariable analysis were PSA at diagnosis (p = 0.001), Gleason score (p = 0.04), and age of patient at diagnosis (p < 0.0001).
  • Competing risk analysis distinguishing the types of death is underway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964248.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Yuan J, Orlandi F, Jefferson M, Li H, Gallardo H, Ku G, Wolchok J, Scher H, Allison J, Slovin SF: Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi). J Clin Oncol; 2009 May 20;27(15_suppl):e16149

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied pts who were treated on a clinical trial with Ipi 10 mg/kg alone or with radiation to a single site in bone to determine whether there was any correlation between serum cytokine levels and autoimmune AEs.
  • METHODS: Thirteen pts were treated, of whom 10 had sufficient specimens for analysis.
  • Pts were stratified by ascertainment of clinical benefit (CB) vs. no clinical benefit (NCB) based on time-to-PSA-baseline relapse (TTBR) and also by toxicity (tox) using standard NCI tox criteria.
  • TTBR was defined as time from study entry until the time when a PSA measurement reached or exceeded the baseline value.
  • Sera at serial time points were analyzed for interferon-gamma (IFN-γ), tumor necrosis factor α and interleukins (IL)-1b, 2, 4, 8, 10, 12, 13 with the Meso Scale Discovery Multiplex Assay (MSD, Gaithersburg, MD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Granberg C, Thompson RH, Quevedo JF, Karnes RJ, Frank I, Kwon ED, Blute ML: Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy. J Clin Oncol; 2009 May 20;27(15_suppl):e16103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, 5/85 patients have electively opted for off-study RP with extended pelvic lymphadenectomy after documentation of robust treatment response by PSA, staging digital rectal exam, and 3-D imaging.
  • One patient is free of disease with undetectable PSA for 19 months following adjuvant radiation treatment but no further therapy, while the other patient is awaiting follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963333.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Baden J, Markiewicz J, Painter J, Jones J, Curtin K, Canning S, Quijano J, Guinto W, Wang Y, Green G: Informative rate and reproducibility of the investigational GeneSearch ProCaM assay in a multicenter laboratory setting. J Clin Oncol; 2009 May 20;27(15_suppl):e22038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22038 Background: PSA tests have low specificity, which frequently results in unnecessary biopsy and typically limits screening to patients with PSA values >4.0 ng/mL.
  • Urine sample results for these samples showed that the areas under the curve for the 3 unique ProCaM Test Kit lots were equivalent (0.72, 0.74, 0.75, p > 0.263).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963156.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Boccardo F: An open, randomized, multicentre, phase III trial comparing the efficacy of two tamoxifen (T) schedules in preventing gynecomastia (gy) induced by bicalutamide monotherapy (BM) in prostate cancer patients (pca pts). J Clin Oncol; 2009 May 20;27(15_suppl):e16080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We had previously demonstrated that T is safe and effective in preventing breast events induced by BM without affecting B tumor activity (Boccardo, J Clin Oncol. 2005;23:808).
  • Gy (primary endpoint), breast pain (bp), serum PSA levels and sexual functioning scores were evaluated.
  • There were no major differences among treat. schedules relative to sexual functioning scores, PSA behaviour and disease progression.
  • CONCLUSIONS: This study failed to demonstrate that it might be possible to maintain comparable prophylactic effect of T by switching from a daily to a weekly schedule and confirms that T at the daily dose of 20mg is safe and effective in preventing the incidence and severity of BM induced breast events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963100.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Droz J, Culine S: Results of a phase II study of carboplatin and etoposide in patients with progressive metastatic castration refractory prostate cancer (mCRPC) and neuro-endocrine differentiation. J Clin Oncol; 2009 May 20;27(15_suppl):e16073

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed the efficacy and toxicity of a platin-based chemotherapy regimen in patients with mCPRC and neuro-endocrine differentiation defined by: either increased circulating neuro-endocrine markers (chromogranin A: CgA, Neuron Specific Enolase: NSE) more than 1.5 X normal serum values and/or visceral metastases confirmed with immunihistochemical proof of neuro-endocrine differentiation on pathological sample.
  • METHODS: Sixty patients were included (Simon optimal two stages design with P0 = 20%, P1 = 40%, α = 5% and power 90% for a total of 54 evaluable patients) and were treated by the combination of carboplatin AUC 4 d1 IV and etoposide 100 mg/m<sup>2</sup>/d d1-3 IV every 3 weeks for a maximum of 6 cycles.
  • Efficacy endpoints included PSA and neuro-endocrine marker response rate (defined as a decrease of 50% or greater of the baseline serum value), objective response rate (according to RECIST criteria), and toxicity.
  • The PSA response rate was 9%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963045.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ: Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol; 2009 May 20;27(15_suppl):5061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary endpoints were: changes in PSA, bone scans and tumor size, bone metabolism [urinary N-telopeptide (uNTX) and bone alkaline phosphatase (BAP)] and PK.
  • Preliminary analysis showed no interaction between dasatinib and D.
  • PSA response was seen in 13/32 (41%) pts, clinical benefit (PR + SD) for RECIST-evaluable pts was 21/21, [7 PR, 5 uPR and 4 SD (at ≥21 wks) and 5 SD at ≥6 wk)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962978.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, Srinivas S, Cogswell J, Morales E, Ahmed S: Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression. J Clin Oncol; 2009 May 20;27(15_suppl):e16019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In an IRB approved study,42 pts had adequate tissue preserved between 1992 and 2006 and their charts were reviewed retrospectively.IHC stains to detect tumor expression of S6(ribosomal),p70s6,pTEN,AKT-1,BCL-1(Cyclin D1),VEGF,c-KIT,PDGFR-alpha and PDGFR-beta were performed by US Labs(Irvine,CA).All results were independently evaluated by two pathologists.Immunoreactivity was scored using a semiquantitative system combining intensity of staining(0-3+) and percentage of cells staining positive(0-3+).The total score was obtained by adding the scores for indensity and the percentage of positive cells,then averaging the resuts obtained by each reader.For the purpose of this study, stain intensity of 0-1+ was considered negative and the intensity of 2-3+ was considered positive.A Cox regression survival model for each stain was developed with variables known to predict survival :Gleason score,Hemoglobin(Hgb),Alkaline Phosphatase(Alk Phos),Prostate Specific Antigen(PSA),Lactate Dehydrogenase(LDH) levels.
  • RESULTS: The median values were: age 70yrs(56-92),Gleason score 8(6-10), LDH 171 IU/L(97-350),Hgb 12.9gm/dl (6.8-16.3), PSA 188ng/ml(2-5677),Alk Phos 139U/L(60-1756),survival 851 days(163- 6102).In univariate analysis,VEGF staining was predictive of survival (p<0.037) but not in multivariate analysis.The pTEN staining correlated with survival (p<0.0367) and a hazard ratio of 0.040 in multivariate analysis.
  • CONCLUSIONS: In this small sample of pts, overexpression of S6,p70s6,AKT-1,BCL-1,VEGF,c-KIT,PDGFR-alpha and PDGFR-beta by IHC staining did not predict survival independently.The pTEN staining,however was strong predictor of survival in the multivariate analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Poiesz B, Reeves J, McNulty W, Maleski J, Holmlund J, Leopold L: Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AT-101 is active as a single agent and in combinations with standard therapies in in vitro and in vivo tumor models, as a single agent in a phase II trial in CRPC, and in combination with D/P as first-line therapy in CRPC, as demonstrated by declines in PSA and RECIST responses.
  • Patients (pts) must have PSA progression per the Bubley criteria or documented disease progression while receiving prior D/P therapy.
  • Safety (NCI CTCAE v3.0) and efficacy (Bubley Criteria for PSA) were assessed at 3-wk intervals.
  • Thirty-five percent (12/34) of pts treated had at least a 30% decrease in PSA level and 18% (6/34) of pts achieved a >50% PSA decline.
  • Twenty one of 34 pts included in this analysis had measurable disease.
  • Five pts (24%) with measurable disease had a PR or CR by RECIST criteria and one additional patient had tumor shrinkage of 29%.
  • Durable PSA and RECIST responses were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964445.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. McHugh C, Madigan K, Walsh A, Fox J, Leonard TW, Quint JB: MER-101-03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5161

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study population consisted of men with hormone refractory prostate cancer as evidenced by history of rising PSA levels (last 2 of 3 PSA levels must be above nadir), who are bisphosphonate-naive, and have radiographically-confirmed bone metastases.
  • Efficacy assessments: The primary endpoints are the assessment of response of four biomarkers, urinary NTX, serum CTX, serum bone specific alkaline phosphatase, and serum calcium on days -7, 0, 7, 14, 21, 28, 35, 42, 49, and 56.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964481.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B: Correlation of hypoxic prostate/muscle p&lt;sub&gt;O2&lt;/sub&gt; (P/M P&lt;sub&gt;O2&lt;/sub&gt;) ratio and biochemical failure in patients with localized prostate cancer: Long-term results. J Clin Oncol; 2009 May 20;27(15_suppl):5136

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5136 Background: Tumor hypoxia may confer radioresistance in prostate cancer.
  • The purpose of this study was to correlate tumor oxygenation status with long term biochemical outcome following prostate bracytherapy.
  • Biochemical failure (BF) was defined using both the newer Phoenix (PSA nadir + 2 ng/mL) the prior ASTRO (three consecutive rises) definitions (dfn).
  • On stepwise multivariate analysis, P/M ratio < 0.10 was a significant predictor of BF (ASTRO, p = 0.03; Phoenix p = 0.02) in a model including initial PSA, Gleason score, T-stage, perineural invasion, age, hemoglobin and use of hormonal therapy.
  • CONCLUSIONS: Hypoxia in prostate cancer (low P/M P<sub>O2</sub> ratio) significantly predicts for poor long term biochemical outcome on multivariate analysis, suggesting that novel hypoxic strategies should be investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Cooperberg MR, Broering JM, Carroll PR: Local variation in primary treatment of localized prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Descriptive analyses were performed, and a random effects logit hierarchical model was constructed, controlling for year of diagnosis, age, comorbidity, PSA, Gleason score, clinical T stage, and percent of biopsy cores positive, to estimate the proportion of variation in primary treatment selection explicable by practice site.
  • Analyses were conducted for all patients and for low-risk patients (Gleason score ≤6, PSA ≤10 ng/ml, clinical stage ≤T2a).
  • CONCLUSIONS: These data do not represent a random sampling of the United States population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Carreca I, Bellomo F, Burgio S, D'Alia P, Piazza D, Russo S, Balducci L: Impact of VEGF and CgA as new predictive tools in management of elderly hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum PSA and plasmatic CgA and VEGF were evaluated in all pts at baseline (T0) and at 4 months (T4) and 8 months (T8) after therapy.
  • PSA response rate (RR) was observed in 10/22 (45%); clinical objective RR was 33% (7/22).
  • The most relevant data in this study refer to the role of serum CgA and VEGF levels, for prediction of tumour response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Rathkopf DE, Chi KN, Vaishampayan U, Hotte S, Vogelzang N, Alumkal J, Agrawal M, Nydam TM, Fandi A, Scher HI: Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-one pts (Cohort 1, n = 8; Cohort 2, n = 10; Cohort 3, n = 3) have been treated, with a median age of 66 yrs (range 50-88), median Gleason score of 9 (range 7-9), and median entry PSA of 67.1 (range 1.3-7920).
  • Five and four pts had >30% and >50% PSA reduction from baseline, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Lu-Yao G, Albertsen PC, Moore DF, Lin Y, Shih W, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, DiPaola RS, Yao S: Outcomes of conservatively managed localized prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cancer-specific and overall mortality, assessed through competing risk analyses, were determined for 14,516 men aged 65 years or older diagnosed between 1992-2002 and did not receive surgery or radiation within 6 months of cancer diagnosis.
  • The population-based cohort was identified from US cancer registries, which had 98% completeness in case ascertainment.
  • RESULTS: Compared to earlier era studies, survival has improved considerably for conservatively managed patients diagnosed in the contemporary prostate specific antigen (PSA) era ( Table ).
  • CONCLUSIONS: Men diagnosed with prostate cancer in the PSA era have survival outcomes significantly better than those in the past.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Gross ME, Soscia J, Sakowsky S, Castellanos O, Agus DB: Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5154

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efficacy is explored as: maximal confirmed PSA decline; partial or complete response (PR+CR) by RECIST criteria; and/or changes in bone scintigraphy.
  • Baseline median (range) values include: age 70 (58-78) yrs, PSA 115 (4-1336) ng/mL, alkaline phosphatase 107 (37-763) U/L.
  • All pts had PSA elevations, 5 pts had metastasis to lung and/or lymph nodes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964476.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Eisenberger MA, Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, DeWeese T, Song D: Phase I trial with a combination of docetaxel and &lt;sup&gt;153&lt;/sup&gt;Sm- EDTMP in patients (pts) with castration-resistant metastatic prostate cancer (mCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5155

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disease status was assessed (with bone /CT scans and PSA) after every cycle.
  • Median baseline PSA was 100.4 ng/ml (range 8.6 - 1064), 9/13 (69%) pts had PSA>50% decrease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964475.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Guix B, Bartrina J, Tello J, Quinzanos L, Lacorte T: Dose escalation by high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Early results of a prospective comparative trial. J Clin Oncol; 2009 May 20;27(15_suppl):5118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between December 1999 and October 2005, 445 patients (pts) with PSA'10, Gleason score'6 and/or T2b-T3 N0 M0 prostate cancer entered the study.
  • Special attention to local, regional or distant recurrence, survival, late effects, PSA and testosterone levels and quality of life was done.
  • With a mean follow-up of 55 months, the 5-year actuarial PSA relapse-free survival rates for intermediate- and high-risk group 1 pts were 92 and 91 % respectively and 97 and 96 % for group 2 pts (p < 0.06).
  • Short-term PSA control rates tends to be better with in the HDR-boosted patients as spected by higher effective-dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964387.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Ponsky LE, Lillibridge C, Brindle J, Zhang Y, Wessels B, Einstein DB: Stereotactic robotic radiosurgery for localized prostate cancer: Initial evaluation of acute toxicities. J Clin Oncol; 2009 May 20;27(15_suppl):e16006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-two patients with low or low-intermediate risk prostate cancer (T2a, GG 3+3=6 or 3+4=7, PSA <10) were enrolled prospectively on an IRB approved protocol and treated the planning target volume (PTV)(prostate+5mm margin) with cyberknife fractionated radiosurgery to a dose of 36.25 Gy in 5 fractions (7.25Gy/fraction).
  • PSA values, AUA symptom scores (AUA SS), and NCI CTC acute toxicities were analyzed prior to radiosurgery and at 1 month (N=16), 3 months (N=12) and 6 months (N=5)post-treatment.
  • Mean pre-treatment PSA was 5.29 (range 0.64-9.36) declining to 3.44 (range 0.00-10.43) at 1 month post treatment, 1.99 (range 0.31-3.99) at 3 months post-treatment and 2.08 (1.05-3.13) at 6 months post-treatment.
  • One developed bacteremia after the transrectal ultrasound guided placement of the fiducials, the infection completely resolved after treatment with antibiotics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962931.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Nguyen PL, Chen MH, Beard CJ, Loffredo M, Renshaw AA, Suh WW, Kantoff PW, D'Amico AV: Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol; 2009 May 20;27(15_suppl):5129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa).
  • METHODS: Among 206 men with clinical T1b-T2b PCa and at least 1 unfavorable feature (PSA>10 or Gleason >=7 or MRI evidence of T3 disease) randomized to 70Gy of RT with or without 6 months of AST, we performed post-randomization subgroup analyses within four subgroups defined by both risk group (high risk [Gleason 8-10 or PSA >20] or intermediate risk [all others]), and by ACE-27 comorbidity level (no/limited comorbidity or moderate/severe comorbidity).
  • Within the 4 subgroups a log-rank test was used to compare Kaplan Meier estimates of survival (requiring p < 0.05/4 or p < 0.0125 to adjust for multiple comparisons) and within the 2 risk groups we used Cox multivariable analysis (MVA) to assess the association of treatment with the risk of death after adjusting for known prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. McDevitt J, Hauser R, Simon J, Balducci L: A dose-escalating phase I study of biweekly docetaxel in older men with hormone refractory prostate cancer (HRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study will also explore the feasibility of a self-report geriatric assessment tool in this population.
  • Five patients had a ≥50% decline in serum PSA on two consecutive measurements taken at least 2 weeks apart.
  • The administration of the VES-13 was feasible in this population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963314.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Elshaikh MA, Abdel Hafeez Z, Lu M, Ibrahim D, El Masry T, Yousef A: The effect of androgen deprivation therapy on CD4/CD8 T cells in HIV-negative patients receiving definitive 3D radiation treatment for their prostate carcinoma: Final report of a prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):11056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had a baseline total testosterone level (T), PSA, CD4 and CD8 T cell counts.
  • CONCLUSIONS: CD4/CD8 T cell counts are sensitive to changes in total testosterone levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963161.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Goldkorn A, Xu T: Targeting prostate cancer progenitor cells with telomerase interference: A novel therapeutic strategy. J Clin Oncol; 2009 May 20;27(15_suppl):e22029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22029 Background: We investigated whether telomerase, which is critical for benign stem cell activation, also plays a role in prostate cancer progenitor cells (PCPCs), which are thought to mediate therapy resistance and cancer progression, and we tested whether telomerase interference can effectively inhibit PCPC proliferation.
  • METHODS: A putative PCPC population was isolated from human prostatectomy specimens via collagen attachment and FACS selection for integrin α<sub>2</sub>β<sub>1</sub> and CD<sub>44</sub>.
  • RESULTS: An integrin α<sub>2</sub>β<sub>1</sub><sup>+</sup>CD<sub>44</sub><sup>+</sup> putative PCPC population was isolated from 6 human prostate tumors.
  • This population expressed high levels of "progenitor phenotype" genes (ABCG2, β-catenin, NANOG, Oct3/4) and low levels of "differentiated phenotype" genes (AR and PSA).
  • PCPCs yielded >50 colonies per 1000 cells seeded on collagen after 3 weeks vs. none from FACS<sup>-</sup> cells, and matrigel chamber assay showed 10% of the PCPC population invading over 24 hours vs. none of the FACS<sup>-</sup> population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963140.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kanao K, Shinojima T, Nakashima J, Ohigashi T, Kikuchi E, Miyajima A, Nakagawa K, Oya M: External validation of preoperative nomograms for predicting pathological stage of prostate cancer: Analysis of 716 Japanese cases. J Clin Oncol; 2009 May 20;27(15_suppl):e16078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External validation of preoperative nomograms for predicting pathological stage of prostate cancer: Analysis of 716 Japanese cases.
  • Partin tables were modified and updated twice to reflect a more contemporary condition of prostate cancer stage at diagnosis.
  • The probabilities of organ confined disease for each case were calculated from four nomograms and external validation was performed using ROC analysis and calibration.
  • PSA at diagnosis was 10.45±0.60 (mean±SE).
  • The area under the ROC curve (AUC)of each Tables was 0.619 in 97 Tables, 0.623 in 01 Tables, 0.614 in 07 Tables and 0.614 in Japanese Tables.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963042.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Giri VN, Hughes L, Ruth K: Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men. J Clin Oncol; 2009 May 20;27(15_suppl):5000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we evaluated the Met160Val SNP (rs12329760) in the TMPRSS2 gene with respect to race, FH of PCA, and time to PCA diagnosis.
  • Cox models were used for time to PCA diagnosis by risk genotype.
  • Among 183 White men with familial PCA with > one follow-up visit, those with the CT/TT genotypes were found to have a significantly earlier time to PCA diagnosis vs. the CC genotype (p = 0.0058).
  • In addition, the hazard ratio for PCA among high-risk White men of the CT/TT genotypes vs CC genotype was 2.55 (p = 0.022) after controlling for age and PSA.
  • No trends were seen among AA men for time to PCA diagnosis for any of the Met160Val SNP genotypes.
  • CONCLUSIONS: The T-allele of the Met160Val variant in the TMPRSS2 gene may be informative of time to PCA diagnosis among White men who have a FH of PCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Netto G, Armstrong A, Wood D, Creel P, Partin A, Jimeno A, Rudek M, George D, Gurganus R, Carducci MA: Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Simon 2-stage design using PD efficacy (tumor S6 inhibition > 60%) was utilized.
  • Median pre-treatment PSA was 6.4 ng/dl, age 60y, Gleason 7 in 85%.
  • PD studies demonstrated tumor S6 inhibition in >50% of subjects (median 60% decline, p=0.026 vs. baseline) with no negative effect on the state of Akt phosphorylation (p=0.82) or p27 levels (p=0.10).
  • PBMC S6 activity inhibition did not correlate with tumor S6 inhibition.
  • This dose demonstrated downstream mTOR inhibition in tumor tissue and achieved adequate prostate tissue levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962897.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Shapiro G, Kwak E, Baselga J, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G: Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor response is assessed every 8 weeks.
  • XL147 reduced levels of phosphorylated PI3K pathway components in PBMCs, hair, skin, and tumor tissues in an exposure-dependent manner.
  • In 2 pts dosed at the MTD, reductions of ≥70% in PI3K pathway signaling were observed in tumor tissue without compensatory upregulation of MEK/ERK phosphorylation.
  • One pt with hormone refractory PC has sustained a normalization of PSA levels through 5 months.
  • Inhibition of PI3K pathway signaling has been demonstrated in tumor and surrogate tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961287.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Vourganti S, Stovsky M, Ponsky L, Siroky M, Kipnis V, Fedotoff O, Mikheeva L, Zaslavsky B, Chait A, Jones JS: Evaluation of the prostate-specific antigen/solvent interaction analysis (PSA/SIA) assay for prostate cancer (CaP) diagnosis. J Clin Oncol; 2009 May 20;27(15_suppl):5053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate-specific antigen/solvent interaction analysis (PSA/SIA) assay for prostate cancer (CaP) diagnosis.
  • : 5053 Background: We describe the clinical performance of a novel protein structural assay for prostate cancer (CaP) diagnosis.
  • The assay uses Solvent Interaction Analysis (SIA) to accurately detect changes in PSA isoform composition that differentiate benign and malignant disease, independent of total serum PSA (tPSA).
  • Prior to standard transrectal ultrasound (TRUS) guided biopsy, patients received a digital rectal examination with systematic prostate massage followed by collection of voided urine for use in PSA/SIA.
  • The assay determined the relative distribution of the entire heterogeneous PSA isoform population between two coexisting aqueous phases for diagnostic purposes.
  • Biopsy results were classified as case (malignant, n = 100) or control (benign, n = 122).
  • Receiver operating characteristic performance results demonstrated AUC of = 0.88 for PSA/SIA and 0.58 for tPSA.
  • At a cut-off value of the composite structural index K = 1.73, PSA/SIA displayed sensitivity = 100%, specificity = 80%, PPV = 83%, and NPV = 100%.
  • CONCLUSIONS: PSA/SIA uniquely exploits the inherent structural heterogeneity in PSA resulting in superior diagnostic performance over conventional biopsy selection criteria.
  • We hypothesize that the high specificity of PSA/SIA is actually underestimated by standard prostate biopsy sampling error.
  • Future trials will assess the utility of the assay in the surveillance of CaP patients after definitive local therapy and other applications in the diagnosis and management of CaP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962955.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Storhoff J, Lubben T, Lefebvre P, Holzman T: Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay. J Clin Oncol; 2009 May 20;27(15_suppl):e16146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay.
  • Currently, prostate cancer recurrence is determined by monitoring prostate specific antigen (PSA) levels in patients following treatment, and those patients whose PSA levels rise above the clinical cutoff of 200 pg/mL PSA are defined as having recurrent prostate cancer.
  • For those that do recur and have high PSA doubling times, early salvage radiotherapy confers a significant increase in prostate cancer specific survival (1).
  • We have developed an ultrasensitive assay that measures PSA levels with a limit of detection of 0.5 pg/mL PSA with a CV of less than 20 % at 2 pg/mL.
  • This assay utilizes functionalized gold nanoparticles to label PSA targets captured onto antibody coated glass substrates.
  • The amount of PSA is quantified through silver enhancement of the functionalized gold.
  • In this presentation, we describe the application of this technology in monitoring PSA levels in patients that are approximately 400 fold below the current clinical cutoff as a means of diagnosing prostate cancer recurrence at a much earlier timepoint than current assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963430.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Karakunnel JJ, Gulley JL, Arlen P, Mulquin M, Wright J, Turkbey IB, Choyke P, Figg WD, Dahut W: Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VEGF is implicated in tumor blood vessel formation and in disease progression in several solid tumors.
  • The primary objective is a 30% 6 month probability of progression free survival as determined by clinical (not by PSA rise alone) and radiographic criteria Simon two stage optimal design is being utilized with twelve patients enrolled in the first cohort.
  • There have been 13 of 23 evaluable patients with tumor shrinkage and 4 have met the criteria for partial response.
  • PSA levels have not corresponded well with imaging responses.
  • Additional accrual is required to better characterize the response rate, the discrepancy between PSA and standard imaging changes and establish evidence of clinical correlation for DCE-MRI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Lee DJ, Ritch C, Desai M, McKiernan JM: Interaction of obesity and race in predicting recurrence rates after radical prostatectomy. J Clin Oncol; 2009 May 20;27(15_suppl):5070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective analysis of the Columbia Urologic Oncology Database found that 3,736 consecutive men underwent RP between 1988 and 2008.
  • BCF was defined as a post-surgery PSA level >0.2 ng/mL on > 2 measurements.
  • RESULTS: The 1,461 men had a median age of 60 years, and median pre-operative PSA of 5.5.
  • After adjusting for preoperative PSA level, tumor stage, and Gleason sum, race remained an independent predictor of BCF (HR = 1.65, p = 0.04).
  • An analysis assessing the effect of an interaction between race and BMI demonstrated that hazard ratios for increased BMI did not differ significantly by race.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964259.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Nabhan C, Tolzien K, Lestingi TM, Galvez A, Bitran JD: Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In studies employing docetaxel (D), 35-39% of pts did not complete therapy due to progression and only 45-50% had a PSA response.
  • Median age was 68 (range 61-83), median PSA was 111.2 ng/ml (13.6-1703.9).
  • Median PSA-DT pre-study was 2 months (0.5-6) and median time from last chemotherapy to starting study was 4 weeks.
  • In all, 6 out of 14 pts (42%) had a PSA decline after adding sorafenib and 3 (21%) had stable PSA.
  • Of these 9 pts (PR+SD), 2 never doubled their PSA.
  • Two pts had PSA decline after withdrawing sorafenib.
  • Median TTP for PSA was 3.75 months.
  • PSA responses did not correlate with radiographic changes or clinical benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Kubicek GJ, Kubicek GJ, Brown S, Redfield S: Combined brachytherapy and external beam radiation for prostate cancer in a community setting. J Clin Oncol; 2009 May 20;27(15_suppl):e16147

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median pre-treatment PSA was 8.1 (range 0.3 to 106) and the median Gleason score was 6.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963422.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Scaramuzzino DA, Schulte K, Mack BN, Soriano TF, Fritsche HA: Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70C or less. Int J Biol Markers; 2007 Jul - Sep;22(3):206-213

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70C or less.
  • : The stability of total (t) and free (f) prostate-specific antigen (PSA) in male serum specimens stored at -70C or lower temperature for 4.7 to 4.9 years was studied.
  • Until now, the stability of these analytes in serum has not been evaluated systematically beyond 2 years of storage at -70C.
  • Aliquots of frozen serum were thawed in 2001 and 2006 and assayed for tPSA and fPSA using a Dade Behring Dimension RxL analyzer and reagents. tPSA values ranged from 0.07 to 69.94 and 0.00 to 69.83 ng/mL in 2001 and 2006, respectively, whereas fPSA values for the tested specimens ranged from 0.02 to 5.72 and 0.00 to 5.92, respectively.
  • Deming regression analyses showed agreement in assay values over time as tPSA values yielded a slope of 1.0112 and a y-intercept of 0.0195; fPSA values produced a slope 1.0538 and a y-intercept of -0.0442; f/tPSA values yielded a slope of 0.9631 and a y-intercept of 0.1195.
  • A BlandAltman analysis of the data demonstrated analyte and ratio stability over this time period.
  • We conclude that serum, when collected properly and stored at -70C or lower temperature, may be used for tPSA and fPSA clinical studies for at least 5 years after collection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207134.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


98. Horvath L, Zhao L, Lee B, Brown D, Molloy M, Marx G, Boyer M, Breit S, Sutherland R, Henshall S: Identification of candidate biomarkers of therapeutic response to docetaxel in hormone-refractory prostate cancer by proteomic profiling. J Clin Oncol; 2009 May 20;27(15_suppl):11010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Protein profiling using iTRAQ mass spectrometry compared the PC3-Rx and DTX-sensitive PC3 cells and DTX-resistant PC3-Rx developed by DTX dose-escalation.
  • Plasma/serum samples were collected from 41 men with metastatic HRPC treated with DTX-based chemotherapy (36 with paired samples pre- and post- cycle 1 DTX).
  • Serum/plasma levels of MIC-1 were measured by ELISA.
  • The association between MIC-1 levels, PSA response and overall survival (OS) were assessed by non-parametric tests and Kaplan-Meier survival analysis.
  • In HRPC patients, pre-treatment MIC-1 levels did not correlate with PSA response to treatment (p=0.6).
  • In contrast, increased serum/plasma levels of MIC-1 after cycle one of chemotherapy were associated with DTX resistance (p=0.006) and shorter overall survival (p=0.002).
  • Furthermore, changes in serum/plasma MIC-1 levels are associated with DTX resistance in a correlative human cohort.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963974.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kaliks-Guendelmann R, Santi P, Cardoso A, Del Giglio A: Complete androgen blockade as second-line hormone manipulation and delay of chemotherapy in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We performed a retrospective analysis of all patients with metastatic prostate cancer treated with CAB as second-line hormone manipulation in a single institution after September 2005.
  • We identified 78 patients and evaluated correlations of prostate specific antigen (PSA), Gleason scores, age, type and length of first-line hormone manipulation with OS and PFS during CAB.
  • We did not find any correlation of PFS with type of first-line hormone manipulation (castration vs ARB, p = 0.10), age group (≤70 or >70 years old, p = 0.10), level of PSA at diagnosis (≤50 or >50 ng/mL, p = 0.17) or length of first-line hormone manipulation (≤14m vs >14 m, p = 0.78).
  • There was no significant correlation between PFS and Gleason score at diagnosis (score ≤7 or >7, p = 0.25), nor between the level of testosterone at the beginning of CAB and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Bitran JD, Tolzien K, Lestingi TM, Nabhan C: Maintenance GM-CSF in patients with castration-resistant prostate cancer (CRPC) who maximized their response to chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16155

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maximum response was defined as a <10% change in PSA repeated on two occasions with stable disease (SD) radiographically.
  • Median PSA at enrollment was 56.5 (0.1-566).
  • Median time from initial diagnosis to GM was 70 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement